CN107760680A - 特异性靶向TIM‑3基因的sgRNA和特异性敲除TIM‑3基因的方法 - Google Patents
特异性靶向TIM‑3基因的sgRNA和特异性敲除TIM‑3基因的方法 Download PDFInfo
- Publication number
- CN107760680A CN107760680A CN201611231819.4A CN201611231819A CN107760680A CN 107760680 A CN107760680 A CN 107760680A CN 201611231819 A CN201611231819 A CN 201611231819A CN 107760680 A CN107760680 A CN 107760680A
- Authority
- CN
- China
- Prior art keywords
- dna
- cas
- lag3
- sgrna
- tim3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 47
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 33
- 108091027544 Subgenomic mRNA Proteins 0.000 title claims abstract description 29
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 title abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 54
- 108091033409 CRISPR Proteins 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 18
- 230000001900 immune effect Effects 0.000 claims abstract description 14
- 238000012360 testing method Methods 0.000 claims abstract description 14
- 241000282414 Homo sapiens Species 0.000 claims abstract description 13
- 210000005260 human cell Anatomy 0.000 claims abstract 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 64
- 210000004027 cell Anatomy 0.000 claims description 58
- 101150030213 Lag3 gene Proteins 0.000 claims description 55
- 102000017578 LAG3 Human genes 0.000 claims description 45
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 37
- 238000010362 genome editing Methods 0.000 claims description 36
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 35
- 108091034117 Oligonucleotide Proteins 0.000 claims description 34
- 241000700605 Viruses Species 0.000 claims description 19
- 238000013461 design Methods 0.000 claims description 14
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 238000010008 shearing Methods 0.000 claims description 6
- NMEHNETUFHBYEG-IHKSMFQHSA-N tttn Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 NMEHNETUFHBYEG-IHKSMFQHSA-N 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 238000003501 co-culture Methods 0.000 claims description 4
- 101800005109 Triakontatetraneuropeptide Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 210000002845 virion Anatomy 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 101100401100 Caenorhabditis elegans mes-1 gene Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 504
- 239000013612 plasmid Substances 0.000 description 37
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 22
- 230000002441 reversible effect Effects 0.000 description 21
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 19
- 230000029087 digestion Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 238000005520 cutting process Methods 0.000 description 18
- 230000008685 targeting Effects 0.000 description 16
- 238000003197 gene knockdown Methods 0.000 description 15
- 238000001514 detection method Methods 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 13
- 238000012545 processing Methods 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000007541 cellular toxicity Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000003209 gene knockout Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101150116295 CAT2 gene Proteins 0.000 description 3
- 101100326920 Caenorhabditis elegans ctl-1 gene Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 101100126846 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) katG gene Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101100329224 Coprinopsis cinerea (strain Okayama-7 / 130 / ATCC MYA-4618 / FGSC 9003) cpf1 gene Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 2
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108091028113 Trans-activating crRNA Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 101150036080 at gene Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 101150059443 cas12a gene Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150014742 AGE1 gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 101150005393 CBF1 gene Proteins 0.000 description 1
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100329225 Coprinopsis cinerea (strain Okayama-7 / 130 / ATCC MYA-4618 / FGSC 9003) cpf2 gene Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101100113998 Mus musculus Cnbd2 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明基于CRISPR系统,提供了一种特异性靶向人‑TIM3基因的sgRNAs和特异性敲除人类细胞中TIM‑3基因的方法。利用本发明提供的sgRNA能够精确有效的靶向人TIM‑3基因并实现基因的精准敲除,具有效率高、周期短、成本低的优异特性。所述方法能够用于制备TIM‑3免疫检查点敲除的人类T细胞,进而将其用于肿瘤免疫治疗。
Description
技术领域
本发明属于基因工程领域,其涉及利用CRISPR-Cas9系统对细胞,尤其是T细胞进行基因编辑的方法,具体为利用CRISPR-Cas9特异性敲除人T细胞中的TIM-3基因的方法。
背景技术
免疫检查点是一系列的免疫抑制分子。正常情况下,免疫检查点对于维持自身免疫耐受、避免免疫系统在对抗病原性感染时对自身器官的攻击起到重要作用,而多种癌症正是通过免疫检查点蛋白表达失调来实现免疫逃避的。通过阻断免疫检查点,恢复机体自身抗肿瘤免疫应答,借助机体免疫功能来清除体内癌细胞一直是肿瘤学家和肿瘤患者的梦想。
目前,在癌症免疫治疗中最重要、研究最多的两个免疫检查点分子是T淋巴细胞抗原-4(cytotoxic T-lymphocyte antigen-4,CTLA-4)和程序性死亡-1(programmed death-1,PD-1)。LAG-3、TIM-3、LAG-3H(VISTA)、BTLA、CD160、2B4、LAIR1、TIGIT、KIRs等免疫检查点也逐渐成为肿瘤免疫治疗所关注的重点对象,相继有多种针对上述靶点的抗体药物处于临床前或临床研究阶段。
LAG-3分子主要表达于活化的NK细胞、T淋巴细胞表面,与HLA-II高亲和力结合,参与淋巴细胞的活化。LAG-3与哮喘、I型糖尿病、肿瘤、慢性病毒感染等多种疾病之间存在紧密联系。TIM-3在Th1,Tc1,Treg以及NK,树突状细胞,肥大细胞,单核巨噬细胞和淋巴管内皮细胞均组成性或诱导性表达,而这些细胞恰恰是构成肿瘤微环境的主要成分,因此该分子在肿瘤免疫中的作用备受重视。
但是,利用抗体进行靶基因的治疗受到一些因素的限制:(1)抗体的作用只是暂时阻断的作用;(2)抑制性受体有多种,如何利用多种抗体同时阻断多种抑制性受体还没有对策;(3)不容易研发出有效的抗体;(4)肿瘤突变多样化,抗体的抑制作用存在局限性;(5)只针对细胞外靶点;(6)抗体药物昂贵等等。
Clustered regularly interspaced short palindromic repeats(CRISPR)/CRISPR-associated(Cas)被称为第三代人工核酸内切酶,可用于各种复杂基因组的编辑。由于其突变效率高、靶向精准、操作简单、周期短及成本低的特点,被认为是一种具有广阔应用前景的基因组定点改造分子工具。Cas9靶向切割DNA是通过两种小RNA-crRNA(CRISPRRNA)和tracrRNA(trans-activating crRNA)和靶序列互补识别的原理实现的。现在已经把两种小RNA融合成一条RNA链,简称sgRNA(single guide RNA)。因此,sgRNA能否做到特异性、精确靶向目标基因是CRISPR-Cas9能否特异性敲除目标基因的先决条件。因此,能够设计、制备出精确性和特异性靶向目标基因的sgRNA成为CRISPR-Cas9基因敲除的关键技术。
利用CRISPR系统进行针对免疫检查点的基因编辑则为实现肿瘤免疫治疗提供了另外一种快速、简便、高效的可行策略。本发明的目的即在于提供精确、特异靶向LAG-3、TIM-3、PD-1基因的sgRNA的设计筛选方法,以及根据相应方法设计获得的sgRNA序列,使用上述sgRNA特异性敲除T细胞中LAG-3、TIM-3、P D-1基因,并使用上述多基因敲除的T细胞处理肿瘤细胞,为实现肿瘤免疫治疗提供一种新的路径。
参考文献:
Drew M.Pardoll.The blockade of immune checkpoints in cancer immunotherapy.Nature Rev.Cancer,2012;12:252-264.
Lieping Chen et al.Molecular mechanisms of T cell co-stimulation andco-inhibition.Nature Rev.Immunology,2013;13:227-242.
Padmanee Sharma et al.Immune Checkpoint Targeting in Cancer Therapy:Toward Combination Strategies with Curative Potential.Cell,161,April 9,2015.
Feng Z et al.Efficient genome editing in plants using a CRISPR/Cassyst em.Cell Res.2013 Oct;23(10):1229-32.
Zetsche B,Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.Cell.2015 Oct 22;163(3):759-71.
发明内容
为解决上述问题,本发明根据一定原则设计、合成、筛选了多组利用CRISP R-Cas9、CRISPR-Cpf1特异性敲除人LAG-3基因(SEQ ID NO.1)的靶向sgRNA;构建包含Cas9内切酶或者Cpf1的CDS序列的载体PMH001-Cas9(SEQ ID NO.478)或者PMH002-Cpf1(SEQ IDNO.479);将上述sgRNA分别与线性的PMH001-Cas9或者PMH002-Cpf1质粒连接构建为PMH001-Cas9-sgLAG3或者PMH002-Cpf1-sgLAG3基因编辑载体;将构建好的基因编辑载体成功转染细胞即可实现LAG-3基因的敲除。
本发明还设计了针对TIM-3(SEQ ID NO.2)靶点的sgRNA,可实现TIM-3基因的敲除。
本发明设计了针对PD-1(SEQ ID NO.3)的sgRNA,将靶向LAG-3、PD-1、TIM-3基因的sgRNA进行组合,分别或共同连接入载体质粒,构建为能够同时敲除多个靶基因的基因编辑系统。
本发明所述基因编辑系统可使用逆转录病毒载体、慢病毒载体、腺病毒载体、腺相关病毒载体、非病毒载体等。
本发明提供了一种经过上述基因编辑系统编辑后的细胞(非人类胚胎干细胞),尤其是人类T细胞。
本发明提供了一种对人类T细胞进行免疫检查点基因编辑的方法,其中涉及对选自PD-1、LAG-3和/或TIM-3中一个或多个靶点的基因编辑。
本发明提供了一种抑制人肿瘤细胞增殖的方法,使用免疫检查点经过基因编辑的T细胞与人肿瘤细胞共培养;所述人肿瘤选自肺癌、胃癌、肝癌和/或乳腺癌;所述肿瘤细胞可选自MHCC97H,LM3,SMCC7721,HepG2,Hep3B,A549,SPC-A1,NCI-H1650,NCI-H1975,NCI-H460,SK-MES-1,MKN-45,MGC-803,NCI-N87,SNU-5,KATO III,HGC-27,BGC-823,SGC-7901,AGS,Bcap-37,MCF-7或SKBR3。
本发明提供了一种使用多靶点基因编辑T细胞治疗肿瘤的方法,所述肿瘤选自肺癌、肝癌、胃癌等。
本申请的具体技术方案如下:
一、sgRNA寡核苷酸的设计和选择
1、靶向靶基因的sgRNA的设计:所述靶基因涉及PD-1、LAG-3、TIM-3等。
因为没有使用体外转录,只是构建普通载体的方式制作,所以如无特殊说明,文中的sgRNA序列指的是sgRNA对应DNA序列。
A.Cas-sgRNA的设计原则:
(1)在靶基因上选择5’-N(21)GG或者5’-N(21)AG。
(2)sgRNA在靶基因上的靶向位点或者剪切位点位于基因的外显子。
(3)sgRNA在靶基因上的靶向位点或者剪切位点位于不同的各种剪切形式的共有外显子上。
(4)在UCSC数据库中用Blat或NCBI数据库中用BLAST,确定sgRNA的靶序列是否唯一。
B.Cpf-sgRNA的设计原则:
(1)在靶基因上选择5’TTTN(20)序列。步骤(2)-(4)同设计原则A。
2、靶向靶基因的sgRNA的选择:
Cas-sgRNA和Cpf-sgRNA的初筛原则:
(1)选择的sgRNA切点保证位于基因编码区。
(2)sgRNA在靶基因上的靶向位点位于整个基因的前半段,尤其宜在基因的功能结构域中;
(3)选择相隔一定距离(10-30bp)成对的位点。这样有利于形成特异性的片段缺失,也有利于降低脱靶效应。
(4)如果基因有多种剪切形式,选择靶向不同剪切形式中的相同序列区域的sgRNA。
二、构建合成sgRNA的寡聚核苷酸双链
1、CRISPR/CAS9sgRNA寡核苷酸双链构建合成:
根据选择的sgRNA,在其5’端加上CACCG得到正向寡核苷酸(Forward oligo)(如果序列本身在5’端已经有1个G,那么就对应的省略1个G);根据选择的sgRNA,获得其对应DNA的互补链,并且在其5’端加上AAAC得到反向寡核苷酸(Reverse oligo)(如果正向链的5’加的是CACCG,则要在反向寡核苷酸链的3’端加C)。分别合成上述正向寡核苷酸和反向寡核苷酸,将合成的sgRNA寡聚核苷酸的Forward oligo和Reverse oligo成对变性、退火,退火之后形成可以连入表达载体的双链,如下:
Forward oligo:5′-CACCGNNNNNNNNNNNNNNNNNN
Reverse oligo:-------------CNNNNNNNNNNNNNNNNNNCAAA-5′
2、CRISPR/CPF1sgRNA寡核苷酸双链构建合成:
根据选择的sgRNA,在其5’端加上AGAT得到正向寡核苷酸(Forward oligo);根据选择的sgRNA,获得其对应DNA的互补链,并且在其5’端加上AAAA得到反向寡核苷酸(Reverse oligo)。分别合成上述正向寡核苷酸和反向寡核苷酸,将合成的sgRNA寡聚核苷酸的Forward oligo和Reverse oligo成对变性、退火,退火之后形成可以连入表达载体的双链,如下:
Forward oligo:5′-AGATNNNNNNNNNNNNNNNNNNNN
Reverse oligo:----------------NNNNNNNNNNNNNNNNNNNNAAAA-5′
三、sgRNA基因编辑质粒的构建
1、用限制性内切酶BBSI线性化PMH001-Cas9或者PMH002-Cpf1质粒(质粒结构如图1、2所示)。
2、将退火的sgRNA寡聚核苷酸双链与线性化PMH001-Cas9或者PMH002-Cpf1质粒连接获得基因编辑质粒,例如,PMH001-Cas9-sgLAG3或者PMH002-Cpf1-sgLAG3质粒。
3、转化并涂Amp+平板(100μg/ml)。
4、37℃摇床摇菌过夜,用快速质粒小提试剂盒(DP105)提取质粒DNA。
5、用通用引物hU6.F测序的方法鉴定阳性克隆。
四、转染细胞获得靶基因敲除细胞
1、依照LipofectamineTM2000Transfection Reagent(Invitrogen,11668-019)的操作手册,将分别带有对应sgRNA寡聚核苷酸的基因编辑质粒(例如,PMH001-Cas9-sgLAG3或者PMH002-Cpf1-sgLAG3质粒(可以携带1种或者多种sgRNA)转染细胞。培养一段时间后提取细胞基因组DNA,PCR扩增sgRNA编辑区域。
2、用T7EN1酶切检测和TA克隆测序确认靶基因已经被敲除。
五、免疫检查点靶基因敲除T细胞的制备
1、靶向敲除LAG-3/TIM-3/PD-1基因的重组病毒的制备
2、重组慢病毒Lenti-PD-1-Puro的包装
3、T细胞的分离纯化
4、利用基因重组病毒对T细胞感染和基因编辑
5、FACS鉴定处理后T细胞表面免疫检查点的敲除效率。
六、基因编辑T细胞与肿瘤细胞共培养进行功能验证
检测LAG-3/TIM-3/PD-1多基因敲除的T细胞(MH-T)及感染空载体Lenti-CRISPR/Cas9-Puro的T细胞(CK-T)对肝癌细胞(MHCC97H,LM3,SMCC7721,HepG2,Hep3B)、肺癌细胞(A549,SPC-A1,NCI-H1650,NCI-H1975,NCI-H460,SK-MES-1)、胃癌细胞(MKN-45,MGC-803,NCI-N87,SNU-5,KATO III,HGC-27,BGC-823,SGC-7901,AGS)、乳腺癌细胞(Bcap-37和MCF-7、SKBR3)的体外杀伤效果,按效靶比(3-10):1、1:1或1:(3-10)分别将CK-T或MH-T与肿瘤细胞混合;各组均设3个重复,取3个重复的平均值进行分析。检测时间为共培养第18-24h。
检测IFN-γ、TNF-α和IL-2细胞因子的特异性释放和细胞毒性功能。
采用CytoTox96非放射性细胞毒性检测试剂盒(Promega公司)检测肿瘤细胞裂解。
本申请提供了一种利用Cas9/sgRNA、Cpf1/sgRNA快速、简便、高效、特异性敲除LAG-3、TIM-3,或同时敲除PD-1、LAG-3和TIM-3基因中多个靶基因的策略和方法,并使用经过上述基因编辑的T细胞有效的抑制了肺癌、胃癌、肝癌、乳腺癌肿瘤细胞的增殖,为肿瘤免疫治疗提供了新的路径。本发明有效地解决了利用抗体治疗存在的问题,存在以下优势:1)直接敲除靶基因,可以实现永久抑制效果;2)既可以针对靶基因上的多个编码序列进行同时敲除,也可以同时针对多个靶基因进行敲除;3)提供了高效的sgRNA或sgRNA的组合;4)sgRNA人工合成,能够实现大批量、快速生产;5)特定免疫检查点组合敲除的T细胞与肿瘤细胞共培养时,能够更高效的诱导T细胞分泌IFN-γ、TNF-α和IL-2细胞因子,并对肿瘤细胞具有更强的杀伤效果。
附图说明
图1.PMH001-Cas9质粒结构图。
图2.PMH002-Cpf1质粒结构图。
图3a.T7EN1酶切鉴定Cas-sgRNA介导的人LAG-3基因特异性切割。
图3b.T7EN1酶切鉴定Cpf-sgRNA介导的人LAG-3基因特异性切割。
图3c.T7EN1酶切鉴定Cas-sgRNA介导的人TIM-3基因特异性切割。
图3d.T7EN1酶切鉴定Cpf-sgRNA介导的人TIM-3基因特异性切割。
图4a.Cas-sgRNA介导的位点特异性人LAG-3切割测序结果,(-)表示敲除区域;sgLAG3-1#即对应Cas-LAG3-sg#6(SEQ ID NO.9)。
图4b.Cpf-sgRNA介导的位点特异性人LAG-3切割测序结果,(-)表示敲除区域;sgLAG3-1#CPF1即对应Cpf-LAG3-sg#1(SEQ ID NO.281)。
图5a.Cas-sgRNA介导的多基因特异性切割酶切鉴定图:同时编辑LAG-3和PD-1。
图5b.Cas-sgRNA介导的多基因特异性切割酶切鉴定图:同时编辑TIM-3和PD-1。
图5c.Cas-sgRNA介导的多基因特异性切割酶切鉴定图:同时编辑LAG-3、TIM-3和PD-1。
图6a.FACS分析T细胞处理前后细胞表面PD-1的敲除率:左侧图示处理前T细胞,右侧图示基因编辑处理后T细胞。
图6b.FACS分析T细胞处理前后细胞表面LAG-3的敲除率:左侧图示处理前T细胞,右侧图示基因编辑处理后T细胞。
图6c.FACS分析T细胞处理前后细胞表面TIM-3的敲除率:左侧图示处理前T细胞,右侧图示基因编辑处理后T细胞。
图7a.IFN-γ细胞因子的效应检测结果。
图7b.TNF-α细胞因子的效应检测结果。
图7c.IL-2细胞因子的效应检测结果。
图8.CytoTox96非放射性细胞毒性检测结果。
具体实施方式
下面结合附图和具体的实施例对本发明的技术方案做进一步介绍。
实施例1 CRISPR-Cas9/Cpf1特异性敲除人LAG-3、TIM-3或PD-1基因的靶向性sgRNA的设计和合成
1、靶向人LAG-3、TIM-3或PD-1基因的Cas-sgRNA的设计:
(1)在LAG-3、TIM-3或PD-1基因上选择5’-N(21)GG的序列,或者5’-N(21)AG。
(2)sgRNA在LAG-3、TIM-3或PD-1基因上的靶向位点或者剪切位点位于基因的外显子,这样更容易引起片段的缺失或移框突变,从而达到基因完全失活的目的。
(3)sgRNA在LAG-3、TIM-3或PD-1基因上的靶向位点或者剪切位点位于不同的各种剪切形式的共有外显子上。
(4)在UCSC数据库中用Blat或NCBI数据库中用BLAST,确定sgRNA的靶序列是否唯一,减少潜在的脱靶位点。
根据以上方法,本发明共设计了277个靶向人LAG-3基因的sgRNA,命名为Cas-LAG3-sg#1-#277,序列分别如序列表SEQ ID NO.4-280所示;
设计了129个靶向人TIM-3基因的sgRNA,命名为Cas-TIM3-sg#1-#129,序列分别如序列表SEQ ID NO.302-430所示;
设计了10个靶向人PD-1基因的sgRNA,命名为Cas-PD1-sg#1-#10,序列分别如序列表SEQ ID NO.468-477所示。
2、靶向人LAG-3、TIM-3或PD-1基因的Cas-sgRNA的选择:
(1)靶向LAG-3、TIM-3或PD-1基因的Cas-sgRNA的切点保证位于基因编码区。
(2)sgRNA在LAG-3、TIM-3或PD-1基因上的靶向位点位于整个基因的前半段,尤其宜在基因的功能结构域中。
(3)在LAG-3、TIM-3或PD-1基因上选择相隔一定距离(10-30bp)成对的位点。这样有利于形成特异性的片段缺失,也有利于降低脱靶效应。
(4)如果基因有多种剪切形式,选择靶向不同剪切形式中的相同序列区域的sgRNA。
根据以上方法,在277个靶向人LAG-3基因的Cas-sgRNA(序列分别如序列表SEQ IDNO.4-280所示)中符合要求的序列有数十个,从中选择了6个Cas-sgRNA(分别如序列表SEQID NO.9、46-50所示)进行后续实验。
同样的,在129个靶向人TIM-3基因的Cas-sgRNA(序列分别如序列表SEQ IDNO.302-430所示)中符合要求的序列大于10个,从中选择了6个(分别如序列表SEQ IDNO.305-307、310、312、313所示)进行后续实验。
选择了靶向人PD-1基因的Cas-sgRNA(序列分别如序列表SEQ ID NO.468-477所示)中的2个序列,分别如序列表SEQ ID NO.472、474所示)进行后续实验。
3、靶向人LAG-3或TIM-3基因的Cpf-sgRNA的设计:
(1)LAG-3或TIM-3基因上选择5’TTTN(20)序列。
步骤(2)-(4)同上述方法1。
根据以上方法,本发明共设计了21个靶向人LAG-3基因的sgRNA,命名为Cpf-LAG3-sg#1-#21,序列分别如序列表SEQ ID NO.281-301所示;
设计了37个靶向人TIM-3基因的sgRNA,命名为Cpf-TIM3-sg#1-#37,序列分别如序列表SEQ ID NO.431-467所示。
4、靶向人LAG-3或TIM-3基因的Cpf-sgRNA的选择原则同上述方法2。
根据以上方法,在21个靶向人LAG-3基因的Cpf-sgRNA中选择了6个(分别如序列表SEQ ID NO.281-286所示)进行后续实验。
在37个靶向人TIM-3基因的Cpf-sgRNA中选择了6个(分别如序列表SEQ IDNO.431-436所示)进行后续实验。
5、靶向人LAG-3、TIM-3或PD-1基因的sgRNA寡聚核苷酸的合成:
根据前述方法选择的14个Cas-sgRNA(分别如序列表SEQ ID NO.6、43-47、305-307、310、312、313、472、474所示),在其5’端加上CACCG得到正向寡核苷酸(Forward oligo)(如果序列本身在5’端已经有1个G,那么就对应的省略1个G);根据选择的sgRNA,获得其对应DNA的互补链,并且在其5’端加上AAAC得到反向寡核苷酸(Reverse oligo)(如果正向链的5’加的是CACCG,则要在反向寡核苷酸链的3’端加C)。分别合成上述正向寡核苷酸和反向寡核苷酸,将合成的sgRNA寡聚核苷酸的forward oligo和reverse oligo成对变性、退火,退火之后形成可以连入表达载体的双链,如下:
Forward oligo:5′-CACCGNNNNNNNNNNNNNNNNNN
Reverse oligo:-----------------CNNNNNNNNNNNNNNNNNNCAAA-5′
根据前述方法选择的6个Cpf-sgRNA(分别如序列表SEQ ID NO.281-286、431-436所示),在其5’端加上AGAT得到正向寡核苷酸(Forward oligo);根据选择的sgRNA,获得其对应DNA的互补链,并且在其5’端加上AAAA得到反向寡核苷酸(Reverse oligo)。分别合成上述正向寡核苷酸和反向寡核苷酸,将合成的sgRNA寡聚核苷酸的forward oligo和reverse oligo成对变性、退火,退火之后形成可以连入表达载体的双链,如下:
Forward oligo:5′-AGATNNNNNNNNNNNNNNNNNNNN
Reverse oligo:---------------NNNNNNNNNNNNNNNNNNNNAAAA-5′
上述变性、退火体系为:
在PCR仪中按照以下touch down程序运行:95℃,5min;95-85℃at-2℃/s;85-25℃at-0.1℃/s;hold at4℃。
分别获得用于后续实验验证的Cas-LAG3-sg#6、#43-#47;Cpf-LAG3-sg#1-#6;Cas-TIM3-sg#4-#6、#9、#11、#12;Cpf-TIM3-sg#1-#6;Cas-PD1-sg#5、#7sgRNA寡聚核苷酸。
实施例2sgRNA基因编辑质粒的构建
1、Cas9质粒的构建:
质粒PMH001-Cas9的制备方法参见文献:Le Cong et al.Multiplex GenomeEngineering Using CRISPR/Cas SystemsScience 339,819(2013);(DOI:10.1126/science.1231143),质粒PMH001-Cas9结构图请见图1,完整序列如SEQ ID NO.478所示。
2、Cpf1质粒的构建:
质粒PMH002-Cpf1的制备方法参见文献:Zetsche Bet al.Cpf1is a single RNA-guided endonuclease of a class 2CRISPR-Cas system.Cell.2015;163:759–71.,质粒PMH002-Cpf1结构图请见图2,完整序列如SEQ ID NO.479所示。
3、单sgRNA基因编辑质粒的构建:
(1)线性化上述步骤1、2制备的PMH001-Cas9或者PMH002-Cpf1质粒。
酶切体系和条件如下:
2μg PMH001-Cas9或者PMH002-Cpf1(400ng/μl);
5μl 10x FastDigest Buffer/FastDigest Green Buffer;
1μl BBSI(Fermentas,FD1014);
补水至50μl,37℃孵育3-4小时,每隔一段时间振荡一下并离心以防液滴蒸发至管盖上。酶切完成后纯化回收至20-40μl灭菌水中。
(2)将实施例1构建获得的变性、退火之后的双链sgRNA寡聚核苷酸与线性化的PMH001-Cas9或者PMH002-Cpf1质粒相连获得基因编辑质粒。
连接体系如下:
25℃孵育10分钟。
(3)将上述步骤获得的连接产物转化DH5α感受态细胞并涂Amp+平板,并挑取克隆。
(4)用通用引物hU6.F,常规测序方法鉴定获得阳性克隆。
(5)37℃摇床摇菌过夜培养阳性克隆,抽提质粒,获得:PMH001-Cas9-sgLAG3#6、#43-#47、PMH002-Cpf1-sgLAG3#1-#6、PMH001-Cas9-sgTIM3#4-#6、#9、#11、#12、PMH002-Cpf1-sgTIM3#1-#6、PMH001-Cas9-sgPD1#5、#7。
4、双sgRNA基因编辑质粒的构建:
(1)按照实施例2步骤1-3中所述方法分别构建单sgRNA表达载体,例如,PMH001-Cas9-sgLAG3-#6或PMH001-Cas9-sgTIM3-#5。
(2)以PMH001-Cas9-sgLAG3-#6为模板,通过PCR扩增获得包含U6启动子和转录终止信号的PU6-sgLAG3-#6-T序列。
(3)用XbaI限制性内切酶线性化PMH001-Cas9-sgTIM3-#5载体。具体反应体系如下
2μg PMH001-Cas9-sgTIM3-#5;
5μl 10x FastDigest Buffer/FastDigest Green Buffer;
1μl XbaI(Fermentas,FD0684);
补水至50μl,37℃孵育3-4小时,每隔一段时间振荡一下并离心以防液滴蒸发至管盖上。酶切完成后纯化回收至20-40μl灭菌水中。
(4)将步骤(2)中得到的片段与步骤(3)中对应的线性化载体重组后,转化TOP10大肠杆菌感受态细胞。具体反应体系如下:
(5)摇菌扩增,并提取质粒DNA测序鉴定阳性克隆PMH001-Cas9-sgTIM3-#5-sgLAG3-#6。
本发明中所使用的其余双/多sgRNA基因编辑质粒均参照上述方式构建,在此并不一一描述。
实施例3 利用CRISPR-Cas9特异性敲除人LAG-3或TIM-3基因
1、细胞培养与转染
(1)HEK293T细胞接种培养于DMEM培养基中,其中含10%FBS,penicillin(100U/ml)和streptomycin(100μg/ml)。
(2)在转染前分至12孔板中,待60%-80%密度时进行转染。
(3)按照LipofectamineTM2000Transfection Reagent(Invitrogen,11668-019)的操作手册,将2μg携带靶向LAG-3sgRNA或TIM-3sgRNA的质粒转染至每孔细胞中,6-8小时后换液,并加入Puromycin(Merck,540411)药筛,48小时后收取细胞。
设计实验组和对照组如表1:
表1.CRISPR-Cas9特异性敲除人LAG-3或TIM-3基因实验组设计
2、T7EN1酶切检测
(1)将收集的细胞在裂解液(10μM Tris-HCl,0.4M NaCl,2μM EDTA,1%SDS)中用100μg/ml蛋白酶K裂解消化后,酚-氯仿抽提后溶解到50μl去离子水中。
(2)使用引物hLAG-3test和hTIM-3test进行PCR扩增(引物序列请见表2),回收纯化PCR产物,取200ng统一稀释到20μl进行变性、退火,程序如:95℃,5min;95–85℃at-2℃/s;85–25℃at-0.1℃/s;hold at4℃。
表2.Cas9酶系统hLAG-3test和hTIM-3test引物序列
(3)在20μl体系中加入T7EN1 0.3μl,37℃酶切30分钟后,加入2μl10×LoadingBuffer,用2.5%的琼脂糖胶电泳检测。
酶切结果请见图3a、3c,加入针对人LAG-3、TIM-3的sgRNA的样品都出现了切割条带,并且具有较高的切割效率,使用双sgRNA进行编辑的实验组的切割效率明显优于单sgRNA切割组。
3、TA克隆测序
(1)将T7EN1酶切检测步骤(2)获得的PCR回收产物用rTaq进行加A反应。加A
反应体系为:
补水至50μl体系,37℃温育30分钟后,取1μl产物与pMD19-T vector连接并转化DH5α感受态细胞。
(2)挑取单克隆以通用引物U6测序,根据测序结果发现:靶基因LAG-3、TIM-3缺失了sgRNA靶向的一段序列,基因敲除成功,见图4。
实施例4 利用CRISPR-Cpf1特异性敲除人LAG-3或TIM-3基因
1、细胞培养与转染
细胞培养与转染方法与实施例3相同,设计实验组和对照组如表3所示:
表3.CRISPR-Cpf1特异性敲除人LAG-3或TIM-3基因实验组设计
实验组 | sgRNA编号 | SEQ ID NO. |
cpf1 | Cpf-LAG3-sg#1 | 281 |
cpf2 | Cpf-LAG3-sg#2 | 282 |
cpf3 | Cpf-LAG3-sg#3 | 283 |
cpf4 | Cpf-LAG3-sg#1+#4 | 281、284 |
cpf5 | Cpf-LAG3-sg#2+#5 | 282、285 |
cpf6 | Cpf-LAG3-sg#3+#6 | 283、286 |
cpf7 | Cpf-LAG3-sg#5+#6 | 285、286 |
cpf8 | Cpf-TIM3-sg#1 | 431 |
cpf9 | Cpf-TIM3-sg#2 | 432 |
cpf10 | Cpf-TIM3-sg#3 | 433 |
cpf11 | Cpf-TIM3-sg#1+#3 | 431、433 |
cpf12 | Cpf-TIM3-sg#2+#4 | 432、434 |
cpf13 | Cpf-TIM3-sg#3+#5 | 433、435 |
cpf14 | Cpf-TIM3-sg#5+#6 | 435、436 |
对照组 | PMH002-Cpf1空载体 | 479 |
2、T7EN1酶切检测
(1)将收集的细胞在裂解液(10μM Tris-HCl,0.4M NaCl,2μM EDTA,1%SDS)中用100μg/ml蛋白酶K裂解消化后,酚-氯仿抽提后溶解到50μl去离子水中。
(2)使用引物hLAG-3test和hTIM-3test进行PCR扩增(引物序列请见表4),回收纯化PCR产物,取200ng统一稀释到20μl进行变性、退火,程序如:95℃,5min;95–85℃at-2℃/s;85–25℃at-0.1℃/s;hold at4℃。
表4.Cpf1酶系统hLAG-3test和hTIM-3test引物序列
(3)在20μl体系中加入T7EN10.3μl,37℃酶切30分钟后,加入2μl10×LoadingBuffer,用2.5%的琼脂糖胶电泳检测。
酶切结果请见图3b、3d,加入针对人LAG-3、TIM-3的sgRNA的样品都出现了切割条带,并且具有较高的切割效率,使用双sgRNA进行编辑的实验组的切割效率明显优于单sgRNA切割组。
3、TA克隆测序
TA克隆测序的方法与实施例3相同,根据测序结果发现:靶基因LAG-3、TIM-3缺失了sgRNA靶向的一段序列,基因敲除成功。
实施例5 利用CRISPR-Cas9特异性敲除多个靶基因
细胞培养与转染、T7EN1酶切检测、TA克隆测序的具体方法与实施例3-4相同,设计实验组和对照组如表5所示:
表5.CRISPR-Cas9特异性敲除多个靶基因实验组设计
实验组 | sgRNA编号 | SEQ ID NO. |
cas15 | Cas-PD1-#5-LAG3-#6 | 472、9 |
cas16 | Cas-PD1-#7-TIM3-#5 | 474、306 |
cas17 | Cas-PD1-#5-TIM3-#5-LAG3-#46 | 472、306、49 |
对照组 | PMH001-Cas9空载体 | 478 |
酶切结果请见图5a-c,加入针对人LAG-3、TIM-3、PD-1的sgRNA的样品都出现了切割条带,并且具有较高的切割效率;测序结果亦显示靶基因敲除成功,即实现了同时敲除人类细胞上的多个免疫检查点基因。
实施例6 利用CRISPR-Cas9特异性敲除多个靶基因的T细胞的制备
1、靶向敲除LAG-3/TIM-3/PD-1基因的重组病毒的制备
1)采用EcoR1、Age1核酸内切酶和磷酸酶37℃处理30分钟使Lenti-CRISPR/Cas9质粒(Addgene 52961)去磷酸化,得到Lenti-CRISPR/Cas9-Puro质粒;
2)以Cas-PD1-#5、TIM3-#5、LAG3-#46sgRNA序列作为LAG-3/TIM-3/PD-1特异性引导RNA,依照实施例1、2、5所述方法合成构建双链sgRNA寡聚核苷酸;
3)使用T4连接酶将上述步骤2)获得的双链sgRNA寡聚核苷酸与步骤1)所得Lenti-CRISPR/Cas9-Puro质粒连接,室温孵育10分钟即可得到重组病毒质粒Lenti-CRISPR/Cas-sgRNA-Puro。
2、重组逆转录病毒Lenti-PD-1-Puro的包装
1)将重组病毒质粒Lenti-CRISPR/Cas-sgRNA-Puro转入Stbl3细菌,经氨苄青霉素筛选,菌种扩增,病毒质粒纯化,测序鉴定,具体步骤如下:
菌种筛选:将转入质粒的细菌种在含氨苄青霉素(100微克/毫升)的琼脂板上,37℃孵育12-16小时后长出菌落,选择3到6个的菌落进行扩增;
菌种扩增:将上述选择的菌落放入300毫升含氨苄青霉素(100微克/毫升)的LB细菌培养液,37℃摇床孵育12-16小时,细菌大量扩增;
质粒纯化:用质粒大抽试剂盒进行提纯,得到1到2毫克病毒质粒;
测序鉴定:将提取的病毒质粒进行测序,选择序列100%正确匹配的病毒质粒进行后续实验验证。
2)转染前一天接种293T细胞到10cm培养皿中,细胞密度以第二天长到细胞70-80%汇合为宜;细胞培养基为DMEM,其中含10%胎牛血清、5000U/ml抗生素(3000U/ml氨苄青霉素和2000U/ml链霉素);
3)转染前2小时换新鲜细胞培养基,将重组病毒质粒Lenti-CRISPR/Cas-sgRNA-Puro与辅助包装质粒pSPAX、pMD2.G转染试剂混合到1.5ml离心管中;其中,Lenti-CRISPR/Cas-sgRNA-Puro、pSPAX、pMD2.G的混合比例为4:3:1;
4)将混合液轻轻混匀后室温放置10分钟,加入10ml细胞培养基中,轻摇混匀;
5)细胞培养箱37℃,5%CO2培养6小时后,更换新鲜细胞培养基;
6)再培养48小时后收集富含病毒的培养基,用0.45um的滤器过滤后分装保存于-80℃,可直接用于感染T细胞。
3、T细胞的分离与富集
T细胞分离的样本来自于健康志愿者的外周血,具体分离纯化步骤如下:
1)静脉采血30毫升,并加入含50u/毫升肝素的PBS溶液30毫升;
2)在2个50毫升离心管中分别加入20毫升Ficoll-paque plus,
3)将步骤1)稀释后的静脉血30毫升分别加到Ficoll的上层,应注意保持两者界面清晰;
4)20℃,400g/分钟离心30分钟,明显分层,取中间层细胞到50毫升离心管中;
5)加入30毫升PBS重悬细胞后,100g/分钟,离心5分钟;
6)重复步骤4)后,计数培养T细胞。
4、利用基因重组病毒对肿瘤T细胞进行感染和基因编辑
1)用30ng/毫升IL-2活化T细胞72小时;
2)将步骤2收集的病毒培养基与T细胞培养基(RPMI1640含10%胎牛血清)按1:1(v/v)混合后感染T细胞,同时加入10μg/毫升polybrener增加感染效率;
3)感染T细胞24小时后,收集并离心T细胞,更换新鲜培养基(含10%胎牛血清的RPMI 1640)培养48小时,收集并离心T细胞,经细胞记数后用生理盐水冲洗2-3次。
4)使用LAG-3、TIM-3、PD-1荧光抗体标记,采用流式分析(FACS)鉴定基因编辑效率:经上述多基因编辑修饰过的T细胞(MH-T)鉴定结果见图6,左侧图片均为处理前T细胞,右侧图片为经过基因编辑处理的T细胞(MH-T)。由图6a-c可见,T细胞(CD3+)经过基因编辑后,PD-1的表达量由对照组的65.77%下降至处理组的8.46%,敲除率可达87.14%;LAG-3的表达量由对照组的44.66%下降至处理组的4.49%,敲除率可达89.95%;TIM-3的表达量由对照组的62.31%下降至处理组的32.68%,敲除率可达47.55%。
实施例7 LAG-3/TIM-3/PD-1多基因敲除的T细胞功能验证
检测实施例6获得的LAG-3/TIM-3/PD-1多基因敲除的T细胞(MH-T)及感染空载体Lenti-CRISPR/Cas9-Puro的T细胞(CK-T)对对肝癌细胞(MHCC97H,LM3,SMCC7721,HepG2,Hep3B)、肺癌细胞(A549,SPC-A1,NCI-H1650,NCI-H1975,NCI-H460,SK-MES-1)、胃癌细胞(MKN-45,MGC-803,NCI-N87,SNU-5,KATO III,HGC-27,BGC-823,SGC-7901,AGS)、乳腺癌细胞(Bcap-37和MCF-7、SKBR3)的体外杀伤效果。具体操作步骤如下:
(1)靶细胞培养:分别接种A549、HepG2、MKN-45、及SKBR3于96/孔板;
(2)效应细胞接种:按效靶比1:5、1:1或5:1分别加入CK-T或MH-T;
(3)实验设计:实验分组情况请详见表6,各组均设3个重复,取平均值进行分析,检测时间为接种效应细胞后培养20h。
表6.基因编辑T细胞功能验证实验分组
(4)检测方法:
a.检测IFN-γ、TNF-α和IL-2细胞因子的靶-特异性释放。实验结果如图7 所示,由图中可以看出,不论效靶比的高低,经过基因编辑的MH-T较对照组的IFN-γ的分泌量都明显增高,随效靶比的增加,IFN-γ分泌量显著提升。MH-T组的IL-2、TNF-g也都表现出高水平表达的趋势,证明基因编辑后的T细胞确实能够对多种肿瘤细胞产生更强的应答反应。
b.采用CytoTox96非放射性细胞毒性检测试剂盒(Promega)检测肿瘤细胞体外裂解情况。
该方法是基于比色法的定量地测量乳酸脱氢酶(LDH)的检测方法,可替代51Cr释放法。LDH是一种稳定的胞质酶,在细胞裂解时会释放出来,其释放方式与51Cr在放射性分析中的释放方式基本相同。释放出的LDH培养基上清中,可通过30分钟偶联的酶反应来检测,在酶反应中LDH可使一种四唑盐(INT)转化为红色的甲臜产物。生成的红色产物的量与裂解的细胞数成正比。常用的96孔读板仪可以收集可见光的吸光度值,该方法可以检测细胞介导的细胞毒作用中(该作用中靶细胞被效应细胞所裂解)的胞膜完整性。
具体操作参照CytoTox96非放射性细胞毒性检测试剂盒说明书进行。
测量参数a | 实验组释放LDH |
测量参数b | 靶细胞自发释放LDH |
测量参数c | 效应细胞自发释放LDH |
测量参数d | 靶细胞最大释放LDH |
细胞毒性计算公式如下:
MH-T细胞对A549、HepG2、MKN-45、及SKBR3的杀伤效果如图8所示。结果显示,LAG-3/TIM-3/PD-1多基因敲除的T细胞对A549、HepG2、MKN-45、及SKBR3细胞的杀伤作用明显优于对照T细胞,效靶比5:1时均可杀伤60%以上的肿瘤细胞,具体肿瘤细胞杀伤效率请见下表。
本文引用的所有专利、专利申请和出版物的公开内容在此都通过引用全文并入。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
SEQUENCE LISTING
<110> 北京微旋基因技术有限公司
<120> 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
<160> 497
<170> PatentIn version 3.3
<210> 1
<211> 1578
<212> DNA
<213> LAG-3
<400> 1
atgtgggagg ctcagttcct gggcttgctg tttctgcagc cgctttgggt ggctccagtg 60
aagcctctcc agccaggggc tgaggtcccg gtggtgtggg cccaggaggg ggctcctgcc 120
cagctcccct gcagccccac aatccccctc caggatctca gccttctgcg aagagcaggg 180
gtcacttggc agcatcagcc agacagtggc ccgcccgctg ccgcccccgg ccatcccctg 240
gcccccggcc ctcacccggc ggcgccctcc tcctgggggc ccaggccccg ccgctacacg 300
gtgctgagcg tgggtcccgg aggcctgcgc agcgggaggc tgcccctgca gccccgcgtc 360
cagctggatg agcgcggccg gcagcgcggg gacttctcgc tatggctgcg cccagcccgg 420
cgcgcggacg ccggcgagta ccgcgccgcg gtgcacctca gggaccgcgc cctctcctgc 480
cgcctccgtc tgcgcctggg ccaggcctcg atgactgcca gccccccagg atctctcaga 540
gcctccgact gggtcatttt gaactgctcc ttcagccgcc ctgaccgccc agcctctgtg 600
cattggttcc ggaaccgggg ccagggccga gtccctgtcc gggagtcccc ccatcaccac 660
ttagcggaaa gcttcctctt cctgccccaa gtcagcccca tggactctgg gccctggggc 720
tgcatcctca cctacagaga tggcttcaac gtctccatca tgtataacct cactgttctg 780
ggtctggagc ccccaactcc cttgacagtg tacgctggag caggttccag ggtggggctg 840
ccctgccgcc tgcctgctgg tgtggggacc cggtctttcc tcactgccaa gtggactcct 900
cctgggggag gccctgacct cctggtgact ggagacaatg gcgactttac ccttcgacta 960
gaggatgtga gccaggccca ggctgggacc tacacctgcc atatccatct gcaggaacag 1020
cagctcaatg ccactgtcac attggcaatc atcacagtga ctcccaaatc ctttgggtca 1080
cctggatccc tggggaagct gctttgtgag gtgactccag tatctggaca agaacgcttt 1140
gtgtggagct ctctggacac cccatcccag aggagtttct caggaccttg gctggaggca 1200
caggaggccc agctcctttc ccagccttgg caatgccagc tgtaccaggg ggagaggctt 1260
cttggagcag cagtgtactt cacagagctg tctagcccag gtgcccaacg ctctgggaga 1320
gccccaggtg ccctcccagc aggccacctc ctgctgtttc tcatccttgg tgtcctttct 1380
ctgctccttt tggtgactgg agcctttggc tttcaccttt ggagaagaca gtggcgacca 1440
agacgatttt ctgccttaga gcaagggatt caccctccgc aggctcagag caagatagag 1500
gagctggagc aagaaccgga gccggagccg gagccggaac cggagcccga gcccgagccc 1560
gagccggagc agctctga 1578
<210> 2
<211> 906
<212> DNA
<213> TIM-3
<400> 2
atgttttcac atcttccctt tgactgtgtc ctgctgctgc tgctgctact acttacaagg 60
tcctcagaag tggaatacag agcggaggtc ggtcagaatg cctatctgcc ctgcttctac 120
accccagccg ccccagggaa cctcgtgccc gtctgctggg gcaaaggagc ctgtcctgtg 180
tttgaatgtg gcaacgtggt gctcaggact gatgaaaggg atgtgaatta ttggacatcc 240
agatactggc taaatgggga tttccgcaaa ggagatgtgt ccctgaccat agagaatgtg 300
actctagcag acagtgggat ctactgctgc cggatccaaa tcccaggcat aatgaatgat 360
gaaaaattta acctgaagtt ggtcatcaaa ccagccaagg tcacccctgc accgactcgg 420
cagagagact tcactgcagc ctttccaagg atgcttacca ccaggggaca tggcccagca 480
gagacacaga cactggggag cctccctgat ataaatctaa cacaaatatc cacattggcc 540
aatgagttac gggactctag attggccaat gacttacggg actctggagc aaccatcaga 600
ataggcatct acatcggagc agggatctgt gctgggctgg ctctggctct tatcttcggc 660
gctttaattt tcaaatggta ttctcatagc aaagagaaga tacagaattt aagcctcatc 720
tctttggcca acctccctcc ctcaggattg gcaaatgcag tagcagaggg aattcgctca 780
gaagaaaaca tctataccat tgaagagaac gtatatgaag tggaggagcc caatgagtat 840
tattgctatg tcagcagcag gcagcaaccc tcacaacctt tgggttgtcg ctttgcaatg 900
ccatag 906
<210> 3
<211> 921
<212> DNA
<213> PD-1
<400> 3
cactctggtg gggctgctcc aggcatgcag atcccacagg cgccctggcc agtcgtctgg 60
gcggtgctac aactgggctg gcggccagga tggttcttag actccccaga caggccctgg 120
aaccccccca ccttctcccc agccctgctc gtggtgaccg aaggggacaa cgccaccttc 180
acctgcagct tctccaacac atcggagagc ttcgtgctaa actggtaccg catgagcccc 240
agcaaccaga cggacaagct ggccgccttc cccgaggacc gcagccagcc cggccaggac 300
tgccgcttcc gtgtcacaca actgcccaac gggcgtgact tccacatgag cgtggtcagg 360
gcccggcgca atgacagcgg cacctacctc tgtggggcca tctccctggc ccccaaggcg 420
cagatcaaag agagcctgcg ggcagagctc agggtgacag agagaagggc agaagtgccc 480
acagcccacc ccagcccctc acccaggtca gccggccagt tccaaaccct ggtggttggt 540
gtcgtgggcg gcctgctggg cagcctggtg ctgctagtct gggtcctggc cgtcatctgc 600
tcccgggccg cacgagggac aataggagcc aggcgcaccg gccagcccct gaaggaggac 660
ccctcagccg tgcctgtgtt ctctgtggac tatggggagc tggatttcca gtggcgagag 720
aagaccccgg agccccccgt gccctgtgtc cctgagcaga cggagtatgc caccattgtc 780
tttcctagcg gaatgggcac ctcatccccc gcccgcaggg gctcagctga cggccctcgg 840
agtgcccagc cactgaggcc tgaggatgga cactgctctt ggcccctctg accggcttcc 900
ttggccacca gtgttctgca g 921
<210> 4
<211> 20
<212> DNA
<213> Cas-LAG3-sg #1
<400> 4
atgtgggagg ctcagttcct 20
<210> 5
<211> 20
<212> DNA
<213> Cas-LAG3-sg #2
<400> 5
tgctgtttct gcagccgctt 20
<210> 6
<211> 20
<212> DNA
<213> Cas-LAG3-sg #3
<400> 6
gctgcagaaa cagcaagccc 20
<210> 7
<211> 20
<212> DNA
<213> Cas-LAG3-sg #4
<400> 7
gctgtttctg cagccgcttt 20
<210> 8
<211> 20
<212> DNA
<213> Cas-LAG3-sg #5
<400> 8
gtttctgcag ccgctttggg 20
<210> 9
<211> 20
<212> DNA
<213> Cas-LAG3-sg #6
<400> 9
tgacccctgc tcttcgcaga 20
<210> 10
<211> 20
<212> DNA
<213> Cas-LAG3-sg #7
<400> 10
ctcagccttc tgcgaagagc 20
<210> 11
<211> 20
<212> DNA
<213> Cas-LAG3-sg #8
<400> 11
tcagccttct gcgaagagca 20
<210> 12
<211> 20
<212> DNA
<213> Cas-LAG3-sg #9
<400> 12
agatcctgga gggggattgt 20
<210> 13
<211> 20
<212> DNA
<213> Cas-LAG3-sg #10
<400> 13
ggctgaggtc ccggtggtgt 20
<210> 14
<211> 20
<212> DNA
<213> Cas-LAG3-sg #11
<400> 14
gggctgaggt cccggtggtg 20
<210> 15
<211> 20
<212> DNA
<213> Cas-LAG3-sg #12
<400> 15
ggtcccggtg gtgtgggccc 20
<210> 16
<211> 20
<212> DNA
<213> Cas-LAG3-sg #13
<400> 16
ttcgcagaag gctgagatcc 20
<210> 17
<211> 20
<212> DNA
<213> Cas-LAG3-sg #14
<400> 17
gatcctggag ggggattgtg 20
<210> 18
<211> 20
<212> DNA
<213> Cas-LAG3-sg #15
<400> 18
tgcgaagagc aggggtcact 20
<210> 19
<211> 20
<212> DNA
<213> Cas-LAG3-sg #16
<400> 19
gagatcctgg agggggattg 20
<210> 20
<211> 20
<212> DNA
<213> Cas-LAG3-sg #17
<400> 20
cagccttctg cgaagagcag 20
<210> 21
<211> 20
<212> DNA
<213> Cas-LAG3-sg #18
<400> 21
ccctcctggg cccacaccac 20
<210> 22
<211> 20
<212> DNA
<213> Cas-LAG3-sg #19
<400> 22
gccaggggct gaggtcccgg 20
<210> 23
<211> 20
<212> DNA
<213> Cas-LAG3-sg #20
<400> 23
accaccggga cctcagcccc 20
<210> 24
<211> 20
<212> DNA
<213> Cas-LAG3-sg #21
<400> 24
cccggtggtg tgggcccagg 20
<210> 25
<211> 20
<212> DNA
<213> Cas-LAG3-sg #22
<400> 25
cctcctgggc ccacaccacc 20
<210> 26
<211> 20
<212> DNA
<213> Cas-LAG3-sg #23
<400> 26
ccgggacctc agcccctggc 20
<210> 27
<211> 20
<212> DNA
<213> Cas-LAG3-sg #24
<400> 27
cagaaggctg agatcctgga 20
<210> 28
<211> 20
<212> DNA
<213> Cas-LAG3-sg #25
<400> 28
gcagaaggct gagatcctgg 20
<210> 29
<211> 20
<212> DNA
<213> Cas-LAG3-sg #26
<400> 29
cagccccaca atccccctcc 20
<210> 30
<211> 20
<212> DNA
<213> Cas-LAG3-sg #27
<400> 30
agggggattg tggggctgca 20
<210> 31
<211> 20
<212> DNA
<213> Cas-LAG3-sg #28
<400> 31
cggtggtgtg ggcccaggag 20
<210> 32
<211> 20
<212> DNA
<213> Cas-LAG3-sg #29
<400> 32
ccggtggtgt gggcccagga 20
<210> 33
<211> 20
<212> DNA
<213> Cas-LAG3-sg #30
<400> 33
gagggggatt gtggggctgc 20
<210> 34
<211> 20
<212> DNA
<213> Cas-LAG3-sg #31
<400> 34
acctcagccc ctggctggag 20
<210> 35
<211> 20
<212> DNA
<213> Cas-LAG3-sg #32
<400> 35
ctgggcagga gccccctcct 20
<210> 36
<211> 20
<212> DNA
<213> Cas-LAG3-sg #33
<400> 36
gaaggctgag atcctggagg 20
<210> 37
<211> 20
<212> DNA
<213> Cas-LAG3-sg #34
<400> 37
gcctctccag ccaggggctg 20
<210> 38
<211> 20
<212> DNA
<213> Cas-LAG3-sg #35
<400> 38
gctgggcagg agccccctcc 20
<210> 39
<211> 20
<212> DNA
<213> Cas-LAG3-sg #36
<400> 39
gggggattgt ggggctgcag 20
<210> 40
<211> 20
<212> DNA
<213> Cas-LAG3-sg #37
<400> 40
ttgtggggct gcaggggagc 20
<210> 41
<211> 20
<212> DNA
<213> Cas-LAG3-sg #38
<400> 41
agaaggctga gatcctggag 20
<210> 42
<211> 20
<212> DNA
<213> Cas-LAG3-sg #39
<400> 42
ccagccaggg gctgaggtcc 20
<210> 43
<211> 20
<212> DNA
<213> Cas-LAG3-sg #40
<400> 43
gggctgcagg ggagctgggc 20
<210> 44
<211> 20
<212> DNA
<213> Cas-LAG3-sg #41
<400> 44
ggtggtgtgg gcccaggagg 20
<210> 45
<211> 20
<212> DNA
<213> Cas-LAG3-sg #42
<400> 45
tgtggggctg caggggagct 20
<210> 46
<211> 20
<212> DNA
<213> Cas-LAG3-sg #43
<400> 46
caccgcggcg cggtactcgc 20
<210> 47
<211> 20
<212> DNA
<213> Cas-LAG3-sg #44
<400> 47
agcgcgggga cttctcgcta 20
<210> 48
<211> 20
<212> DNA
<213> Cas-LAG3-sg #45
<400> 48
ctcagcaccg tgtagcggcg 20
<210> 49
<211> 20
<212> DNA
<213> Cas-LAG3-sg #46
<400> 49
cgctcagcac cgtgtagcgg 20
<210> 50
<211> 20
<212> DNA
<213> Cas-LAG3-sg #47
<400> 50
cgctacacgg tgctgagcgt 20
<210> 51
<211> 20
<212> DNA
<213> Cas-LAG3-sg #48
<400> 51
cgccggcgag taccgcgccg 20
<210> 52
<211> 20
<212> DNA
<213> Cas-LAG3-sg #49
<400> 52
gctcagcacc gtgtagcggc 20
<210> 53
<211> 20
<212> DNA
<213> Cas-LAG3-sg #50
<400> 53
ccacgctcag caccgtgtag 20
<210> 54
<211> 20
<212> DNA
<213> Cas-LAG3-sg #51
<400> 54
cgcgtccagc tggatgagcg 20
<210> 55
<211> 20
<212> DNA
<213> Cas-LAG3-sg #52
<400> 55
cgctcatcca gctggacgcg 20
<210> 56
<211> 20
<212> DNA
<213> Cas-LAG3-sg #53
<400> 56
gcgagaagtc cccgcgctgc 20
<210> 57
<211> 20
<212> DNA
<213> Cas-LAG3-sg #54
<400> 57
actcgccggc gtccgcgcgc 20
<210> 58
<211> 20
<212> DNA
<213> Cas-LAG3-sg #55
<400> 58
gcccaggccc cgccgctaca 20
<210> 59
<211> 20
<212> DNA
<213> Cas-LAG3-sg #56
<400> 59
tccagctgga tgagcgcggc 20
<210> 60
<211> 20
<212> DNA
<213> Cas-LAG3-sg #57
<400> 60
gcgctcatcc agctggacgc 20
<210> 61
<211> 20
<212> DNA
<213> Cas-LAG3-sg #58
<400> 61
ccgctacacg gtgctgagcg 20
<210> 62
<211> 20
<212> DNA
<213> Cas-LAG3-sg #59
<400> 62
gccggccgcg ctcatccagc 20
<210> 63
<211> 20
<212> DNA
<213> Cas-LAG3-sg #60
<400> 63
ccagcccggc gcgcggacgc 20
<210> 64
<211> 20
<212> DNA
<213> Cas-LAG3-sg #61
<400> 64
cgcgctcatc cagctggacg 20
<210> 65
<211> 20
<212> DNA
<213> Cas-LAG3-sg #62
<400> 65
aggagggcgc cgccgggtga 20
<210> 66
<211> 20
<212> DNA
<213> Cas-LAG3-sg #63
<400> 66
gatgagcgcg gccggcagcg 20
<210> 67
<211> 20
<212> DNA
<213> Cas-LAG3-sg #64
<400> 67
accgtgtagc ggcggggcct 20
<210> 68
<211> 20
<212> DNA
<213> Cas-LAG3-sg #65
<400> 68
ctcgccggcg tccgcgcgcc 20
<210> 69
<211> 20
<212> DNA
<213> Cas-LAG3-sg #66
<400> 69
caccgtgtag cggcggggcc 20
<210> 70
<211> 20
<212> DNA
<213> Cas-LAG3-sg #67
<400> 70
atgagcgcgg ccggcagcgc 20
<210> 71
<211> 20
<212> DNA
<213> Cas-LAG3-sg #68
<400> 71
acggtgctga gcgtgggtcc 20
<210> 72
<211> 20
<212> DNA
<213> Cas-LAG3-sg #69
<400> 72
ggggcagcct cccgctgcgc 20
<210> 73
<211> 20
<212> DNA
<213> Cas-LAG3-sg #70
<400> 73
cggcgtccgc gcgccgggct 20
<210> 74
<211> 20
<212> DNA
<213> Cas-LAG3-sg #71
<400> 74
gtcccggagg cctgcgcagc 20
<210> 75
<211> 20
<212> DNA
<213> Cas-LAG3-sg #72
<400> 75
ccggcgtccg cgcgccgggc 20
<210> 76
<211> 20
<212> DNA
<213> Cas-LAG3-sg #73
<400> 76
tgagcgcggc cggcagcgcg 20
<210> 77
<211> 20
<212> DNA
<213> Cas-LAG3-sg #74
<400> 77
ggtcccggag gcctgcgcag 20
<210> 78
<211> 20
<212> DNA
<213> Cas-LAG3-sg #75
<400> 78
gtgctgagcg tgggtcccgg 20
<210> 79
<211> 20
<212> DNA
<213> Cas-LAG3-sg #76
<400> 79
ccggaggcct gcgcagcggg 20
<210> 80
<211> 20
<212> DNA
<213> Cas-LAG3-sg #77
<400> 80
cgccgccggg tgagggccgg 20
<210> 81
<211> 20
<212> DNA
<213> Cas-LAG3-sg #78
<400> 81
cctcccgctg cgcaggcctc 20
<210> 82
<211> 20
<212> DNA
<213> Cas-LAG3-sg #79
<400> 82
cctgcagccc cgcgtccagc 20
<210> 83
<211> 20
<212> DNA
<213> Cas-LAG3-sg #80
<400> 83
cgctatggct gcgcccagcc 20
<210> 84
<211> 20
<212> DNA
<213> Cas-LAG3-sg #81
<400> 84
gaggagggcg ccgccgggtg 20
<210> 85
<211> 20
<212> DNA
<213> Cas-LAG3-sg #82
<400> 85
ccccaggagg agggcgccgc 20
<210> 86
<211> 20
<212> DNA
<213> Cas-LAG3-sg #83
<400> 86
gcgccgccgg gtgagggccg 20
<210> 87
<211> 20
<212> DNA
<213> Cas-LAG3-sg #84
<400> 87
ggcccccggc cctcacccgg 20
<210> 88
<211> 20
<212> DNA
<213> Cas-LAG3-sg #85
<400> 88
ctcccgctgc gcaggcctcc 20
<210> 89
<211> 20
<212> DNA
<213> Cas-LAG3-sg #86
<400> 89
ggcgccgccg ggtgagggcc 20
<210> 90
<211> 20
<212> DNA
<213> Cas-LAG3-sg #88
<400> 90
cgggggccag gggatggccg 20
<210> 91
<211> 20
<212> DNA
<213> Cas-LAG3-sg #88
<400> 91
acccggcggc gccctcctcc 20
<210> 92
<211> 20
<212> DNA
<213> Cas-LAG3-sg #89
<400> 92
gggcgccgcc gggtgagggc 20
<210> 93
<211> 20
<212> DNA
<213> Cas-LAG3-sg #90
<400> 93
cccaggagga gggcgccgcc 20
<210> 94
<211> 20
<212> DNA
<213> Cas-LAG3-sg #91
<400> 94
cccggcggcg ccctcctcct 20
<210> 95
<211> 20
<212> DNA
<213> Cas-LAG3-sg #92
<400> 95
ggatggccgg gggcggcagc 20
<210> 96
<211> 20
<212> DNA
<213> Cas-LAG3-sg #93
<400> 96
tgccgccccc ggccatcccc 20
<210> 97
<211> 20
<212> DNA
<213> Cas-LAG3-sg #94
<400> 97
cagctggacg cggggctgca 20
<210> 98
<211> 20
<212> DNA
<213> Cas-LAG3-sg #95
<400> 98
gggggccagg ggatggccgg 20
<210> 99
<211> 20
<212> DNA
<213> Cas-LAG3-sg #96
<400> 99
cggcggcgcc ctcctcctgg 20
<210> 100
<211> 20
<212> DNA
<213> Cas-LAG3-sg #97
<400> 100
ccagctggac gcggggctgc 20
<210> 101
<211> 20
<212> DNA
<213> Cas-LAG3-sg #98
<400> 101
ggcccgcccg ctgccgcccc 20
<210> 102
<211> 20
<212> DNA
<213> Cas-LAG3-sg #99
<400> 102
ccggcggcgc cctcctcctg 20
<210> 103
<211> 20
<212> DNA
<213> Cas-LAG3-sg #100
<400> 103
gctgcgccca gcccggcgcg 20
<210> 104
<211> 20
<212> DNA
<213> Cas-LAG3-sg #101
<400> 104
ccgggggcca ggggatggcc 20
<210> 105
<211> 20
<212> DNA
<213> Cas-LAG3-sg #102
<400> 105
ggccagggga tggccggggg 20
<210> 106
<211> 20
<212> DNA
<213> Cas-LAG3-sg #103
<400> 106
tggccggggg cggcagcggg 20
<210> 107
<211> 20
<212> DNA
<213> Cas-LAG3-sg #104
<400> 107
ggccgggggc ggcagcgggc 20
<210> 108
<211> 20
<212> DNA
<213> Cas-LAG3-sg #105
<400> 108
agctggacgc ggggctgcag 20
<210> 109
<211> 20
<212> DNA
<213> Cas-LAG3-sg #106
<400> 109
gcggcggggc ctgggccccc 20
<210> 110
<211> 20
<212> DNA
<213> Cas-LAG3-sg #107
<400> 110
cgggtgaggg ccgggggcca 20
<210> 111
<211> 20
<212> DNA
<213> Cas-LAG3-sg #108
<400> 111
gggatggccg ggggcggcag 20
<210> 112
<211> 20
<212> DNA
<213> Cas-LAG3-sg #109
<400> 112
gccgggggcc aggggatggc 20
<210> 113
<211> 20
<212> DNA
<213> Cas-LAG3-sg #110
<400> 113
ccgggtgagg gccgggggcc 20
<210> 114
<211> 20
<212> DNA
<213> Cas-LAG3-sg #111
<400> 114
cccggccatc ccctggcccc 20
<210> 115
<211> 20
<212> DNA
<213> Cas-LAG3-sg #112
<400> 115
gcggggcctg ggcccccagg 20
<210> 116
<211> 20
<212> DNA
<213> Cas-LAG3-sg #113
<400> 116
gggtgagggc cgggggccag 20
<210> 117
<211> 20
<212> DNA
<213> Cas-LAG3-sg #114
<400> 117
cctggccccc ggccctcacc 20
<210> 118
<211> 20
<212> DNA
<213> Cas-LAG3-sg #115
<400> 118
cgccctcctc ctgggggccc 20
<210> 119
<211> 20
<212> DNA
<213> Cas-LAG3-sg #116
<400> 119
gagggccggg ggccagggga 20
<210> 120
<211> 20
<212> DNA
<213> Cas-LAG3-sg #117
<400> 120
gggcctgggc ccccaggagg 20
<210> 121
<211> 20
<212> DNA
<213> Cas-LAG3-sg #118
<400> 121
ggcctgggcc cccaggagga 20
<210> 122
<211> 20
<212> DNA
<213> Cas-LAG3-sg #119
<400> 122
ctgccgcctc cgtctgcgcc 20
<210> 123
<211> 20
<212> DNA
<213> Cas-LAG3-sg #120
<400> 123
tgccgcctcc gtctgcgcct 20
<210> 124
<211> 20
<212> DNA
<213> Cas-LAG3-sg #121
<400> 124
caggcgcaga cggaggcggc 20
<210> 125
<211> 20
<212> DNA
<213> Cas-LAG3-sg #122
<400> 125
cctggcccag gcgcagacgg 20
<210> 126
<211> 20
<212> DNA
<213> Cas-LAG3-sg #123
<400> 126
aggcctggcc caggcgcaga 20
<210> 127
<211> 20
<212> DNA
<213> Cas-LAG3-sg #124
<400> 127
ggcccaggcg cagacggagg 20
<210> 128
<211> 20
<212> DNA
<213> Cas-LAG3-sg #125
<400> 128
cctccgtctg cgcctgggcc 20
<210> 129
<211> 20
<212> DNA
<213> Cas-LAG3-sg #126
<400> 129
gcagacggag gcggcaggag 20
<210> 130
<211> 20
<212> DNA
<213> Cas-LAG3-sg #127
<400> 130
cagacggagg cggcaggaga 20
<210> 131
<211> 20
<212> DNA
<213> Cas-LAG3-sg #128
<400> 131
ggaggcggca ggagagggcg 20
<210> 132
<211> 20
<212> DNA
<213> Cas-LAG3-sg #129
<400> 132
gtgcattggt tccggaaccg 20
<210> 133
<211> 20
<212> DNA
<213> Cas-LAG3-sg #130
<400> 133
tgtgcattgg ttccggaacc 20
<210> 134
<211> 20
<212> DNA
<213> Cas-LAG3-sg #131
<400> 134
ctgtgcattg gttccggaac 20
<210> 135
<211> 20
<212> DNA
<213> Cas-LAG3-sg #132
<400> 135
tgatgggggg actcccggac 20
<210> 136
<211> 20
<212> DNA
<213> Cas-LAG3-sg #133
<400> 136
ttggttccgg aaccggggcc 20
<210> 137
<211> 20
<212> DNA
<213> Cas-LAG3-sg #134
<400> 137
gttcaaaatg acccagtcgg 20
<210> 138
<211> 20
<212> DNA
<213> Cas-LAG3-sg #135
<400> 138
agaggaagct ttccgctaag 20
<210> 139
<211> 20
<212> DNA
<213> Cas-LAG3-sg #137
<400> 139
gctttccgct aagtggtgat 20
<210> 140
<211> 20
<212> DNA
<213> Cas-LAG3-sg #137
<400> 140
gatctctcag agcctccgac 20
<210> 141
<211> 20
<212> DNA
<213> Cas-LAG3-sg #138
<400> 141
atctctcaga gcctccgact 20
<210> 142
<211> 20
<212> DNA
<213> Cas-LAG3-sg #139
<400> 142
tggttccgga accggggcca 20
<210> 143
<211> 20
<212> DNA
<213> Cas-LAG3-sg #140
<400> 143
gttccggaac caatgcacag 20
<210> 144
<211> 20
<212> DNA
<213> Cas-LAG3-sg #141
<400> 144
gatgggggga ctcccggaca 20
<210> 145
<211> 20
<212> DNA
<213> Cas-LAG3-sg #142
<400> 145
agctttccgc taagtggtga 20
<210> 146
<211> 20
<212> DNA
<213> Cas-LAG3-sg #143
<400> 146
ctttccgcta agtggtgatg 20
<210> 147
<211> 20
<212> DNA
<213> Cas-LAG3-sg #144
<400> 147
ttccgctaag tggtgatggg 20
<210> 148
<211> 20
<212> DNA
<213> Cas-LAG3-sg #145
<400> 148
gtccccccat caccacttag 20
<210> 149
<211> 20
<212> DNA
<213> Cas-LAG3-sg #146
<400> 149
gacgttgaag ccatctctgt 20
<210> 150
<211> 20
<212> DNA
<213> Cas-LAG3-sg #147
<400> 150
ctcggccctg gccccggttc 20
<210> 151
<211> 20
<212> DNA
<213> Cas-LAG3-sg #148
<400> 151
cccggacagg gactcggccc 20
<210> 152
<211> 20
<212> DNA
<213> Cas-LAG3-sg #149
<400> 152
cagcctctgt gcattggttc 20
<210> 153
<211> 20
<212> DNA
<213> Cas-LAG3-sg #150
<400> 153
gcagttcaaa atgacccagt 20
<210> 154
<211> 20
<212> DNA
<213> Cas-LAG3-sg #151
<400> 154
tttccgctaa gtggtgatgg 20
<210> 155
<211> 20
<212> DNA
<213> Cas-LAG3-sg #152
<400> 155
tgggcggtca gggcggctga 20
<210> 156
<211> 20
<212> DNA
<213> Cas-LAG3-sg #153
<400> 156
gggactcccg gacagggact 20
<210> 157
<211> 20
<212> DNA
<213> Cas-LAG3-sg #154
<400> 157
cggaggctct gagagatcct 20
<210> 158
<211> 20
<212> DNA
<213> Cas-LAG3-sg #155
<400> 158
agagtccatg gggctgactt 20
<210> 159
<211> 20
<212> DNA
<213> Cas-LAG3-sg #156
<400> 159
accgcccagc ctctgtgcat 20
<210> 160
<211> 20
<212> DNA
<213> Cas-LAG3-sg #157
<400> 160
cagagtccat ggggctgact 20
<210> 161
<211> 20
<212> DNA
<213> Cas-LAG3-sg #158
<400> 161
tgcacagagg ctgggcggtc 20
<210> 162
<211> 20
<212> DNA
<213> Cas-LAG3-sg #159
<400> 162
caagtcagcc ccatggactc 20
<210> 163
<211> 20
<212> DNA
<213> Cas-LAG3-sg #160
<400> 163
gccagggccg agtccctgtc 20
<210> 164
<211> 20
<212> DNA
<213> Cas-LAG3-sg #161
<400> 164
gagtccatgg ggctgacttg 20
<210> 165
<211> 20
<212> DNA
<213> Cas-LAG3-sg #162
<400> 165
tgcatcctca cctacagaga 20
<210> 166
<211> 20
<212> DNA
<213> Cas-LAG3-sg #163
<400> 166
tgaagccatc tctgtaggtg 20
<210> 167
<211> 20
<212> DNA
<213> Cas-LAG3-sg #164
<400> 167
gcacagaggc tgggcggtca 20
<210> 168
<211> 20
<212> DNA
<213> Cas-LAG3-sg #165
<400> 168
agtggtgatg gggggactcc 20
<210> 169
<211> 20
<212> DNA
<213> Cas-LAG3-sg #166
<400> 169
aagtcagccc catggactct 20
<210> 170
<211> 20
<212> DNA
<213> Cas-LAG3-sg #167
<400> 170
tcggaggctc tgagagatcc 20
<210> 171
<211> 20
<212> DNA
<213> Cas-LAG3-sg #168
<400> 171
ggaggctctg agagatcctg 20
<210> 172
<211> 20
<212> DNA
<213> Cas-LAG3-sg #169
<400> 172
ccagggccga gtccctgtcc 20
<210> 173
<211> 20
<212> DNA
<213> Cas-LAG3-sg #170
<400> 173
ggaaccaatg cacagaggct 20
<210> 174
<211> 20
<212> DNA
<213> Cas-LAG3-sg #171
<400> 174
ccatggggct gacttggggc 20
<210> 175
<211> 20
<212> DNA
<213> Cas-LAG3-sg #172
<400> 175
ccccagggcc cagagtccat 20
<210> 176
<211> 20
<212> DNA
<213> Cas-LAG3-sg #173
<400> 176
cggaaccaat gcacagaggc 20
<210> 177
<211> 20
<212> DNA
<213> Cas-LAG3-sg #174
<400> 177
taggtgagga tgcagcccca 20
<210> 178
<211> 20
<212> DNA
<213> Cas-LAG3-sg #175
<400> 178
tctgagagat cctggggggc 20
<210> 179
<211> 20
<212> DNA
<213> Cas-LAG3-sg #176
<400> 179
cccagggccc agagtccatg 20
<210> 180
<211> 20
<212> DNA
<213> Cas-LAG3-sg #177
<400> 180
gtaggtgagg atgcagcccc 20
<210> 181
<211> 20
<212> DNA
<213> Cas-LAG3-sg #178
<400> 181
gaggctctga gagatcctgg 20
<210> 182
<211> 20
<212> DNA
<213> Cas-LAG3-sg #179
<400> 182
gccccatgga ctctgggccc 20
<210> 183
<211> 20
<212> DNA
<213> Cas-LAG3-sg #180
<400> 183
aggctctgag agatcctggg 20
<210> 184
<211> 20
<212> DNA
<213> Cas-LAG3-sg #181
<400> 184
ccccatggac tctgggccct 20
<210> 185
<211> 20
<212> DNA
<213> Cas-LAG3-sg #182
<400> 185
cctgccccaa gtcagcccca 20
<210> 186
<211> 20
<212> DNA
<213> Cas-LAG3-sg #183
<400> 186
accaatgcac agaggctggg 20
<210> 187
<211> 20
<212> DNA
<213> Cas-LAG3-sg #184
<400> 187
gccccagggc ccagagtcca 20
<210> 188
<211> 20
<212> DNA
<213> Cas-LAG3-sg #185
<400> 188
cagggactcg gccctggccc 20
<210> 189
<211> 20
<212> DNA
<213> Cas-LAG3-sg #186
<400> 189
ggctgacttg gggcaggaag 20
<210> 190
<211> 20
<212> DNA
<213> Cas-LAG3-sg #187
<400> 190
cccatggact ctgggccctg 20
<210> 191
<211> 20
<212> DNA
<213> Cas-LAG3-sg #188
<400> 191
cagaggctgg gcggtcaggg 20
<210> 192
<211> 20
<212> DNA
<213> Cas-LAG3-sg #189
<400> 192
cgactttacc cttcgactag 20
<210> 193
<211> 20
<212> DNA
<213> Cas-LAG3-sg #190
<400> 193
actcccttga cagtgtacgc 20
<210> 194
<211> 20
<212> DNA
<213> Cas-LAG3-sg #191
<400> 194
ggctcacatc ctctagtcga 20
<210> 195
<211> 20
<212> DNA
<213> Cas-LAG3-sg #192
<400> 195
gctcacatcc tctagtcgaa 20
<210> 196
<211> 20
<212> DNA
<213> Cas-LAG3-sg #193
<400> 196
gcgtacactg tcaagggagt 20
<210> 197
<211> 20
<212> DNA
<213> Cas-LAG3-sg #194
<400> 197
gctccagcgt acactgtcaa 20
<210> 198
<211> 20
<212> DNA
<213> Cas-LAG3-sg #195
<400> 198
tcgactagag gatgtgagcc 20
<210> 199
<211> 20
<212> DNA
<213> Cas-LAG3-sg #196
<400> 199
ttgacagtgt acgctggagc 20
<210> 200
<211> 20
<212> DNA
<213> Cas-LAG3-sg #197
<400> 200
cgtacactgt caagggagtt 20
<210> 201
<211> 20
<212> DNA
<213> Cas-LAG3-sg #198
<400> 201
tgctccagcg tacactgtca 20
<210> 202
<211> 20
<212> DNA
<213> Cas-LAG3-sg #199
<400> 202
ttcctgcaga tggatatggc 20
<210> 203
<211> 20
<212> DNA
<213> Cas-LAG3-sg #200
<400> 203
tgtacgctgg agcaggttcc 20
<210> 204
<211> 20
<212> DNA
<213> Cas-LAG3-sg #201
<400> 204
cgccattgtc tccagtcacc 20
<210> 205
<211> 20
<212> DNA
<213> Cas-LAG3-sg #202
<400> 205
gtacgctgga gcaggttcca 20
<210> 206
<211> 20
<212> DNA
<213> Cas-LAG3-sg #203
<400> 206
gtacactgtc aagggagttg 20
<210> 207
<211> 20
<212> DNA
<213> Cas-LAG3-sg #204
<400> 207
tcccccagga ggagtccact 20
<210> 208
<211> 20
<212> DNA
<213> Cas-LAG3-sg #205
<400> 208
ctgccaagtg gactcctcct 20
<210> 209
<211> 20
<212> DNA
<213> Cas-LAG3-sg #206
<400> 209
tgccaagtgg actcctcctg 20
<210> 210
<211> 20
<212> DNA
<213> Cas-LAG3-sg #207
<400> 210
gctgttcctg cagatggata 20
<210> 211
<211> 20
<212> DNA
<213> Cas-LAG3-sg #208
<400> 211
actgccaagt ggactcctcc 20
<210> 212
<211> 20
<212> DNA
<213> Cas-LAG3-sg #209
<400> 212
cacctgccat atccatctgc 20
<210> 213
<211> 20
<212> DNA
<213> Cas-LAG3-sg #210
<400> 213
gaccgggtcc ccacaccagc 20
<210> 214
<211> 20
<212> DNA
<213> Cas-LAG3-sg #211
<400> 214
tacactgtca agggagttgg 20
<210> 215
<211> 20
<212> DNA
<213> Cas-LAG3-sg #212
<400> 215
gaggagtcca cttggcagtg 20
<210> 216
<211> 20
<212> DNA
<213> Cas-LAG3-sg #213
<400> 216
gccaagtgga ctcctcctgg 20
<210> 217
<211> 20
<212> DNA
<213> Cas-LAG3-sg #214
<400> 217
cattgtctcc agtcaccagg 20
<210> 218
<211> 20
<212> DNA
<213> Cas-LAG3-sg #215
<400> 218
ctccagtcac caggaggtca 20
<210> 219
<211> 20
<212> DNA
<213> Cas-LAG3-sg #216
<400> 219
cagatggata tggcaggtgt 20
<210> 220
<211> 20
<212> DNA
<213> Cas-LAG3-sg #217
<400> 220
ggccctgacc tcctggtgac 20
<210> 221
<211> 20
<212> DNA
<213> Cas-LAG3-sg #218
<400> 221
acttggcagt gaggaaagac 20
<210> 222
<211> 20
<212> DNA
<213> Cas-LAG3-sg #219
<400> 222
tctccagtca ccaggaggtc 20
<210> 223
<211> 20
<212> DNA
<213> Cas-LAG3-sg #220
<400> 223
ggtctttcct cactgccaag 20
<210> 224
<211> 20
<212> DNA
<213> Cas-LAG3-sg #221
<400> 224
ggcaggtgta ggtcccagcc 20
<210> 225
<211> 20
<212> DNA
<213> Cas-LAG3-sg #222
<400> 225
ctcctggtga ctggagacaa 20
<210> 226
<211> 20
<212> DNA
<213> Cas-LAG3-sg #223
<400> 226
gcaggtgtag gtcccagcct 20
<210> 227
<211> 20
<212> DNA
<213> Cas-LAG3-sg #224
<400> 227
acaccagcag gcaggcggca 20
<210> 228
<211> 20
<212> DNA
<213> Cas-LAG3-sg #225
<400> 228
cgctggagca ggttccaggg 20
<210> 229
<211> 20
<212> DNA
<213> Cas-LAG3-sg #226
<400> 229
aggaggtcag ggcctccccc 20
<210> 230
<211> 20
<212> DNA
<213> Cas-LAG3-sg #227
<400> 230
cacaccagca ggcaggcggc 20
<210> 231
<211> 20
<212> DNA
<213> Cas-LAG3-sg #228
<400> 231
gctggagcag gttccagggt 20
<210> 232
<211> 20
<212> DNA
<213> Cas-LAG3-sg #229
<400> 232
gggtccccac accagcaggc 20
<210> 233
<211> 20
<212> DNA
<213> Cas-LAG3-sg #230
<400> 233
tgagctgctg ttcctgcaga 20
<210> 234
<211> 20
<212> DNA
<213> Cas-LAG3-sg #231
<400> 234
tgccgcctgc ctgctggtgt 20
<210> 235
<211> 20
<212> DNA
<213> Cas-LAG3-sg #232
<400> 235
ctgccgcctg cctgctggtg 20
<210> 236
<211> 20
<212> DNA
<213> Cas-LAG3-sg #233
<400> 236
gccgcctgcc tgctggtgtg 20
<210> 237
<211> 20
<212> DNA
<213> Cas-LAG3-sg #234
<400> 237
tgggggaggc cctgacctcc 20
<210> 238
<211> 20
<212> DNA
<213> Cas-LAG3-sg #235
<400> 238
agaggatgtg agccaggccc 20
<210> 239
<211> 20
<212> DNA
<213> Cas-LAG3-sg #236
<400> 239
tgtaggtccc agcctgggcc 20
<210> 240
<211> 20
<212> DNA
<213> Cas-LAG3-sg #237
<400> 240
aggtcagggc ctcccccagg 20
<210> 241
<211> 20
<212> DNA
<213> Cas-LAG3-sg #238
<400> 241
tgcctgctgg tgtggggacc 20
<210> 242
<211> 20
<212> DNA
<213> Cas-LAG3-sg #239
<400> 242
tccccacacc agcaggcagg 20
<210> 243
<211> 20
<212> DNA
<213> Cas-LAG3-sg #240
<400> 243
ctggagcagg ttccagggtg 20
<210> 244
<211> 20
<212> DNA
<213> Cas-LAG3-sg #241
<400> 244
cttggcagtg aggaaagacc 20
<210> 245
<211> 20
<212> DNA
<213> Cas-LAG3-sg #242
<400> 245
aagtggactc ctcctggggg 20
<210> 246
<211> 20
<212> DNA
<213> Cas-LAG3-sg #243
<400> 246
atgtgagcca ggcccaggct 20
<210> 247
<211> 20
<212> DNA
<213> Cas-LAG3-sg #244
<400> 247
gatgtgagcc aggcccaggc 20
<210> 248
<211> 20
<212> DNA
<213> Cas-LAG3-sg #245
<400> 248
ctgccctgcc gcctgcctgc 20
<210> 249
<211> 20
<212> DNA
<213> Cas-LAG3-sg #246
<400> 249
gcggcagggc agccccaccc 20
<210> 250
<211> 20
<212> DNA
<213> Cas-LAG3-sg #247
<400> 250
gagctgctcc ggctcgggct 20
<210> 251
<211> 20
<212> DNA
<213> Cas-LAG3-sg #248
<400> 251
agctgctccg gctcgggctc 20
<210> 252
<211> 20
<212> DNA
<213> Cas-LAG3-sg #249
<400> 252
ggctcacctg tcttctccaa 20
<210> 253
<211> 20
<212> DNA
<213> Cas-LAG3-sg #250
<400> 253
cccagagcgt tgggcaccta 20
<210> 254
<211> 20
<212> DNA
<213> Cas-LAG3-sg #251
<400> 254
gcattctggg gcctcggacc 20
<210> 255
<211> 20
<212> DNA
<213> Cas-LAG3-sg #252
<400> 255
cattctgggg cctcggacct 20
<210> 256
<211> 20
<212> DNA
<213> Cas-LAG3-sg #253
<400> 256
gatgattgcc aatgtgacag 20
<210> 257
<211> 20
<212> DNA
<213> Cas-LAG3-sg #254
<400> 257
aacagtgagg ttatacatga 20
<210> 258
<211> 20
<212> DNA
<213> Cas-LAG3-sg #255
<400> 258
gggctggcag tcactgtgca 20
<210> 259
<211> 20
<212> DNA
<213> Cas-LAG3-sg #256
<400> 259
cgtcccgccc cacatactcg 20
<210> 260
<211> 20
<212> DNA
<213> Cas-LAG3-sg #257
<400> 260
cgccccacat actcgaggcc 20
<210> 261
<211> 20
<212> DNA
<213> Cas-LAG3-sg #258
<400> 261
acatactcga ggcctggccc 20
<210> 262
<211> 20
<212> DNA
<213> Cas-LAG3-sg #259
<400> 262
gcggcagcgg gcgggccact 20
<210> 263
<211> 20
<212> DNA
<213> Cas-LAG3-sg #260
<400> 263
cagcgggcgg gccactgggc 20
<210> 264
<211> 20
<212> DNA
<213> Cas-LAG3-sg #261
<400> 264
ctggctggag aggcttcact 20
<210> 265
<211> 20
<212> DNA
<213> Cas-LAG3-sg #262
<400> 265
cccgccatcc ccgttttacc 20
<210> 266
<211> 20
<212> DNA
<213> Cas-LAG3-sg #263
<400> 266
cccagaccat aggagagatg 20
<210> 267
<211> 20
<212> DNA
<213> Cas-LAG3-sg #264
<400> 267
gaccatagga gagatgtggg 20
<210> 268
<211> 20
<212> DNA
<213> Cas-LAG3-sg #265
<400> 268
cagccgcttt gggtggctcc 20
<210> 269
<211> 20
<212> DNA
<213> Cas-LAG3-sg #266
<400> 269
cttggcagca tcagccagac 20
<210> 270
<211> 20
<212> DNA
<213> Cas-LAG3-sg #267
<400> 270
accgcgccgc ggtgcacctc 20
<210> 271
<211> 20
<212> DNA
<213> Cas-LAG3-sg #268
<400> 271
ccgcgccgcg gtgcacctca 20
<210> 272
<211> 20
<212> DNA
<213> Cas-LAG3-sg #269
<400> 272
acagtgactg ccagcccccc 20
<210> 273
<211> 20
<212> DNA
<213> Cas-LAG3-sg #270
<400> 273
ttttcttttc tcttcaggtc 20
<210> 274
<211> 20
<212> DNA
<213> Cas-LAG3-sg #271
<400> 274
gctcaatgcc actgtcacat 20
<210> 275
<211> 20
<212> DNA
<213> Cas-LAG3-sg #272
<400> 275
tcagtgactc ccaaatcctt 20
<210> 276
<211> 20
<212> DNA
<213> Cas-LAG3-sg #273
<400> 276
ttcacagagc tgtctagccc 20
<210> 277
<211> 20
<212> DNA
<213> Cas-LAG3-sg #274
<400> 277
tccataggtg cccaacgctc 20
<210> 278
<211> 20
<212> DNA
<213> Cas-LAG3-sg #275
<400> 278
ctttcacctt tggagaagac 20
<210> 279
<211> 20
<212> DNA
<213> Cas-LAG3-sg #276
<400> 279
ctctccatct cttctcacag 20
<210> 280
<211> 20
<212> DNA
<213> Cas-LAG3-sg #277
<400> 280
gagccggagc agctctgacc 20
<210> 281
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #1
<400> 281
ctgcagccgc tttgggtggc 20
<210> 282
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #2
<400> 282
tgaactgctc cttcagccgc 20
<210> 283
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #3
<400> 283
cctcactgcc aagtggactc 20
<210> 284
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #4
<400> 284
acccttcgac tagaggatgt 20
<210> 285
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #5
<400> 285
gggtcacctg gatccctggg 20
<210> 286
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #6
<400> 286
gtgaggtgac tccagtatct 20
<210> 287
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #7
<400> 287
gtgtggagct ctctggacac 20
<210> 288
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #8
<400> 288
ctcaggacct tggctggagg 20
<210> 289
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #9
<400> 289
cccagccttg gcaatgccag 20
<210> 290
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #10
<400> 290
ctcatccttg gtgtcctttc 20
<210> 291
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #11
<400> 291
tggtgactgg agcctttggc 20
<210> 292
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #12
<400> 292
ggctttcacc tttggagaag 20
<210> 293
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #13
<400> 293
tctgccttag agcaagggat 20
<210> 294
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #14
<400> 294
ccgctaagtg gtgatggggg 20
<210> 295
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #15
<400> 295
tcagtgactc ccaaatcctt 20
<210> 296
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #16
<400> 296
cagtgactcc caaatccttt 20
<210> 297
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #17
<400> 297
ctccataggt gcccaacgct 20
<210> 298
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #18
<400> 298
cacctttgga gaagacaggt 20
<210> 299
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #19
<400> 299
gggagtcact gaaaagagta 20
<210> 300
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #20
<400> 300
ggggtgcata cctgtctggc 20
<210> 301
<211> 20
<212> DNA
<213> Cpf-LAG3-sg #21
<400> 301
acctggagcc acccaaagcg 20
<210> 302
<211> 20
<212> DNA
<213> Cas-TIM3-sg #1
<400> 302
cagcagcagg acacagtcaa 20
<210> 303
<211> 20
<212> DNA
<213> Cas-TIM3-sg #2
<400> 303
agcagcagga cacagtcaaa 20
<210> 304
<211> 20
<212> DNA
<213> Cas-TIM3-sg #3
<400> 304
gtagtagcag cagcagcagc 20
<210> 305
<211> 20
<212> DNA
<213> Cas-TIM3-sg #4
<400> 305
ctaaatgggg atttccgcaa 20
<210> 306
<211> 20
<212> DNA
<213> Cas-TIM3-sg #5
<400> 306
gaacctcgtg cccgtctgct 20
<210> 307
<211> 20
<212> DNA
<213> Cas-TIM3-sg #6
<400> 307
aatgtggcaa cgtggtgctc 20
<210> 308
<211> 20
<212> DNA
<213> Cas-TIM3-sg #7
<400> 308
atccccattt agccagtatc 20
<210> 309
<211> 20
<212> DNA
<213> Cas-TIM3-sg #8
<400> 309
gagtcacatt ctctatggtc 20
<210> 310
<211> 20
<212> DNA
<213> Cas-TIM3-sg #9
<400> 310
cagacgggca cgaggttccc 20
<210> 311
<211> 20
<212> DNA
<213> Cas-TIM3-sg #10
<400> 311
gtggaataca gagcggaggt 20
<210> 312
<211> 20
<212> DNA
<213> Cas-TIM3-sg #11
<400> 312
agacgggcac gaggttccct 20
<210> 313
<211> 20
<212> DNA
<213> Cas-TIM3-sg #12
<400> 313
ggaacctcgt gcccgtctgc 20
<210> 314
<211> 20
<212> DNA
<213> Cas-TIM3-sg #13
<400> 314
tgtgtttgaa tgtggcaacg 20
<210> 315
<211> 20
<212> DNA
<213> Cas-TIM3-sg #14
<400> 315
aacctcgtgc ccgtctgctg 20
<210> 316
<211> 20
<212> DNA
<213> Cas-TIM3-sg #15
<400> 316
attattggac atccagatac 20
<210> 317
<211> 20
<212> DNA
<213> Cas-TIM3-sg #16
<400> 317
gacgggcacg aggttccctg 20
<210> 318
<211> 20
<212> DNA
<213> Cas-TIM3-sg #17
<400> 318
agaagtggaa tacagagcgg 20
<210> 319
<211> 20
<212> DNA
<213> Cas-TIM3-sg #18
<400> 319
catccagata ctggctaaat 20
<210> 320
<211> 20
<212> DNA
<213> Cas-TIM3-sg #19
<400> 320
tctacacccc agccgcccca 20
<210> 321
<211> 20
<212> DNA
<213> Cas-TIM3-sg #20
<400> 321
acgttgccac attcaaacac 20
<210> 322
<211> 20
<212> DNA
<213> Cas-TIM3-sg #21
<400> 322
ggcggctggg gtgtagaagc 20
<210> 323
<211> 20
<212> DNA
<213> Cas-TIM3-sg #22
<400> 323
ttctacaccc cagccgcccc 20
<210> 324
<211> 20
<212> DNA
<213> Cas-TIM3-sg #23
<400> 324
tgccccagca gacgggcacg 20
<210> 325
<211> 20
<212> DNA
<213> Cas-TIM3-sg #24
<400> 325
acgaggttcc ctggggcggc 20
<210> 326
<211> 20
<212> DNA
<213> Cas-TIM3-sg #25
<400> 326
atccagatac tggctaaatg 20
<210> 327
<211> 20
<212> DNA
<213> Cas-TIM3-sg #26
<400> 327
agtcacattc tctatggtca 20
<210> 328
<211> 20
<212> DNA
<213> Cas-TIM3-sg #27
<400> 328
acatccagat actggctaaa 20
<210> 329
<211> 20
<212> DNA
<213> Cas-TIM3-sg #28
<400> 329
gccacattca aacacaggac 20
<210> 330
<211> 20
<212> DNA
<213> Cas-TIM3-sg #29
<400> 330
tcagggacac atctcctttg 20
<210> 331
<211> 20
<212> DNA
<213> Cas-TIM3-sg #30
<400> 331
cgctctgtat tccacttctg 20
<210> 332
<211> 20
<212> DNA
<213> Cas-TIM3-sg #31
<400> 332
gcggctgggg tgtagaagca 20
<210> 333
<211> 20
<212> DNA
<213> Cas-TIM3-sg #32
<400> 333
gtgcccgtct gctggggcaa 20
<210> 334
<211> 20
<212> DNA
<213> Cas-TIM3-sg #33
<400> 334
gcctgtcctg tgtttgaatg 20
<210> 335
<211> 20
<212> DNA
<213> Cas-TIM3-sg #34
<400> 335
ggtgtagaag cagggcagat 20
<210> 336
<211> 20
<212> DNA
<213> Cas-TIM3-sg #35
<400> 336
gctcctttgc cccagcagac 20
<210> 337
<211> 20
<212> DNA
<213> Cas-TIM3-sg #36
<400> 337
gaggttccct ggggcggctg 20
<210> 338
<211> 20
<212> DNA
<213> Cas-TIM3-sg #37
<400> 338
ctcagaagtg gaatacagag 20
<210> 339
<211> 20
<212> DNA
<213> Cas-TIM3-sg #38
<400> 339
atgaaaggga tgtgaattat 20
<210> 340
<211> 20
<212> DNA
<213> Cas-TIM3-sg #39
<400> 340
cgaggttccc tggggcggct 20
<210> 341
<211> 20
<212> DNA
<213> Cas-TIM3-sg #40
<400> 341
tggtgctcag gactgatgaa 20
<210> 342
<211> 20
<212> DNA
<213> Cas-TIM3-sg #41
<400> 342
ggctcctttg ccccagcaga 20
<210> 343
<211> 20
<212> DNA
<213> Cas-TIM3-sg #42
<400> 343
ggtgctcagg actgatgaaa 20
<210> 344
<211> 20
<212> DNA
<213> Cas-TIM3-sg #43
<400> 344
gggcacgagg ttccctgggg 20
<210> 345
<211> 20
<212> DNA
<213> Cas-TIM3-sg #44
<400> 345
tgctgccgga tccaaatccc 20
<210> 346
<211> 20
<212> DNA
<213> Cas-TIM3-sg #45
<400> 346
ctggtttgat gaccaacttc 20
<210> 347
<211> 20
<212> DNA
<213> Cas-TIM3-sg #46
<400> 347
acagtgggat ctactgctgc 20
<210> 348
<211> 20
<212> DNA
<213> Cas-TIM3-sg #47
<400> 348
ttatgcctgg gatttggatc 20
<210> 349
<211> 20
<212> DNA
<213> Cas-TIM3-sg #48
<400> 349
cattcattat gcctgggatt 20
<210> 350
<211> 20
<212> DNA
<213> Cas-TIM3-sg #49
<400> 350
tttcatcatt cattatgcct 20
<210> 351
<211> 20
<212> DNA
<213> Cas-TIM3-sg #50
<400> 351
ttttcatcat tcattatgcc 20
<210> 352
<211> 20
<212> DNA
<213> Cas-TIM3-sg #51
<400> 352
tgaaaaattt aacctgaagt 20
<210> 353
<211> 20
<212> DNA
<213> Cas-TIM3-sg #52
<400> 353
ctctctgccg agtcggtgca 20
<210> 354
<211> 20
<212> DNA
<213> Cas-TIM3-sg #53
<400> 354
tctctctgcc gagtcggtgc 20
<210> 355
<211> 20
<212> DNA
<213> Cas-TIM3-sg #54
<400> 355
gtgaagtctc tctgccgagt 20
<210> 356
<211> 20
<212> DNA
<213> Cas-TIM3-sg #55
<400> 356
tctctgccga gtcggtgcag 20
<210> 357
<211> 20
<212> DNA
<213> Cas-TIM3-sg #56
<400> 357
aggtcacccc tgcaccgact 20
<210> 358
<211> 20
<212> DNA
<213> Cas-TIM3-sg #57
<400> 358
ccaaggatgc ttaccaccag 20
<210> 359
<211> 20
<212> DNA
<213> Cas-TIM3-sg #58
<400> 359
tccaaggatg cttaccacca 20
<210> 360
<211> 20
<212> DNA
<213> Cas-TIM3-sg #59
<400> 360
cccctggtgg taagcatcct 20
<210> 361
<211> 20
<212> DNA
<213> Cas-TIM3-sg #60
<400> 361
ttccaaggat gcttaccacc 20
<210> 362
<211> 20
<212> DNA
<213> Cas-TIM3-sg #61
<400> 362
ggtggtaagc atccttggaa 20
<210> 363
<211> 20
<212> DNA
<213> Cas-TIM3-sg #62
<400> 363
atgcttacca ccaggggaca 20
<210> 364
<211> 20
<212> DNA
<213> Cas-TIM3-sg #63
<400> 364
agtcggtgca ggggtgacct 20
<210> 365
<211> 20
<212> DNA
<213> Cas-TIM3-sg #64
<400> 365
acttcactgc agcctttcca 20
<210> 366
<211> 20
<212> DNA
<213> Cas-TIM3-sg #65
<400> 366
ataggcatct acatcggagc 20
<210> 367
<211> 20
<212> DNA
<213> Cas-TIM3-sg #66
<400> 367
tctagagtcc cgtaactcat 20
<210> 368
<211> 20
<212> DNA
<213> Cas-TIM3-sg #67
<400> 368
taggcatcta catcggagca 20
<210> 369
<211> 20
<212> DNA
<213> Cas-TIM3-sg #68
<400> 369
tgagttacgg gactctagat 20
<210> 370
<211> 20
<212> DNA
<213> Cas-TIM3-sg #69
<400> 370
tccagagtcc cgtaagtcat 20
<210> 371
<211> 20
<212> DNA
<213> Cas-TIM3-sg #70
<400> 371
ccgtaactca ttggccaatg 20
<210> 372
<211> 20
<212> DNA
<213> Cas-TIM3-sg #71
<400> 372
tagattggcc aatgacttac 20
<210> 373
<211> 20
<212> DNA
<213> Cas-TIM3-sg #72
<400> 373
ccacattggc caatgagtta 20
<210> 374
<211> 20
<212> DNA
<213> Cas-TIM3-sg #73
<400> 374
atcagaatag gcatctacat 20
<210> 375
<211> 20
<212> DNA
<213> Cas-TIM3-sg #74
<400> 375
cacattggcc aatgagttac 20
<210> 376
<211> 20
<212> DNA
<213> Cas-TIM3-sg #75
<400> 376
ctagattggc caatgactta 20
<210> 377
<211> 20
<212> DNA
<213> Cas-TIM3-sg #76
<400> 377
atcggagcag ggatctgtgc 20
<210> 378
<211> 20
<212> DNA
<213> Cas-TIM3-sg #77
<400> 378
gatgtagatg cctattctga 20
<210> 379
<211> 20
<212> DNA
<213> Cas-TIM3-sg #78
<400> 379
tctggagcaa ccatcagaat 20
<210> 380
<211> 20
<212> DNA
<213> Cas-TIM3-sg #79
<400> 380
ctggctctgg ctcttatctt 20
<210> 381
<211> 20
<212> DNA
<213> Cas-TIM3-sg #80
<400> 381
gccaatgact tacgggactc 20
<210> 382
<211> 20
<212> DNA
<213> Cas-TIM3-sg #81
<400> 382
tcggagcagg gatctgtgct 20
<210> 383
<211> 20
<212> DNA
<213> Cas-TIM3-sg #82
<400> 383
agcagggatc tgtgctgggc 20
<210> 384
<211> 20
<212> DNA
<213> Cas-TIM3-sg #83
<400> 384
gatctgtgct gggctggctc 20
<210> 385
<211> 20
<212> DNA
<213> Cas-TIM3-sg #84
<400> 385
gcgacaaccc aaaggttgtg 20
<210> 386
<211> 20
<212> DNA
<213> Cas-TIM3-sg #85
<400> 386
cgacaaccca aaggttgtga 20
<210> 387
<211> 20
<212> DNA
<213> Cas-TIM3-sg #86
<400> 387
gcagcaaccc tcacaacctt 20
<210> 388
<211> 20
<212> DNA
<213> Cas-TIM3-sg #87
<400> 388
attgcaaagc gacaacccaa 20
<210> 389
<211> 20
<212> DNA
<213> Cas-TIM3-sg #88
<400> 389
cagcaaccct cacaaccttt 20
<210> 390
<211> 20
<212> DNA
<213> Cas-TIM3-sg #89
<400> 390
gacatagcaa taatactcat 20
<210> 391
<211> 20
<212> DNA
<213> Cas-TIM3-sg #90
<400> 391
tactgcattt gccaatcctg 20
<210> 392
<211> 20
<212> DNA
<213> Cas-TIM3-sg #91
<400> 392
attattgcta tgtcagcagc 20
<210> 393
<211> 20
<212> DNA
<213> Cas-TIM3-sg #92
<400> 393
actgcatttg ccaatcctga 20
<210> 394
<211> 20
<212> DNA
<213> Cas-TIM3-sg #93
<400> 394
gcatttgcca atcctgaggg 20
<210> 395
<211> 20
<212> DNA
<213> Cas-TIM3-sg #94
<400> 395
catttgccaa tcctgaggga 20
<210> 396
<211> 20
<212> DNA
<213> Cas-TIM3-sg #95
<400> 396
agagaacgta tatgaagtgg 20
<210> 397
<211> 20
<212> DNA
<213> Cas-TIM3-sg #96
<400> 397
acatagcaat aatactcatt 20
<210> 398
<211> 20
<212> DNA
<213> Cas-TIM3-sg #97
<400> 398
ttggcaaatg cagtagcaga 20
<210> 399
<211> 20
<212> DNA
<213> Cas-TIM3-sg #98
<400> 399
attggcaaat gcagtagcag 20
<210> 400
<211> 20
<212> DNA
<213> Cas-TIM3-sg #99
<400> 400
ttgccaatcc tgagggaggg 20
<210> 401
<211> 20
<212> DNA
<213> Cas-TIM3-sg #100
<400> 401
caacctccct ccctcaggat 20
<210> 402
<211> 20
<212> DNA
<213> Cas-TIM3-sg #101
<400> 402
ttcatatacg ttctcttcaa 20
<210> 403
<211> 20
<212> DNA
<213> Cas-TIM3-sg #102
<400> 403
tgaagagaac gtatatgaag 20
<210> 404
<211> 20
<212> DNA
<213> Cas-TIM3-sg #103
<400> 404
ggaggttggc caaagagatg 20
<210> 405
<211> 20
<212> DNA
<213> Cas-TIM3-sg #104
<400> 405
ttggccaacc tccctccctc 20
<210> 406
<211> 20
<212> DNA
<213> Cas-TIM3-sg #105
<400> 406
caatcctgag ggagggaggt 20
<210> 407
<211> 20
<212> DNA
<213> Cas-TIM3-sg #106
<400> 407
tggccaaaga gatgaggctg 20
<210> 408
<211> 20
<212> DNA
<213> Cas-TIM3-sg #107
<400> 408
tatgagaata ccctagtaag 20
<210> 409
<211> 20
<212> DNA
<213> Cas-TIM3-sg #108
<400> 409
gccaatgtgg atatttgcta 20
<210> 410
<211> 20
<212> DNA
<213> Cas-TIM3-sg #109
<400> 410
aaagggaaga tgtgaaaaca 20
<210> 411
<211> 20
<212> DNA
<213> Cas-TIM3-sg #110
<400> 411
ttgggccaca attctctcct 20
<210> 412
<211> 20
<212> DNA
<213> Cas-TIM3-sg #111
<400> 412
ctatgcaggg tcctcagaag 20
<210> 413
<211> 20
<212> DNA
<213> Cas-TIM3-sg #112
<400> 413
aatgtgactc tagcagacag 20
<210> 414
<211> 20
<212> DNA
<213> Cas-TIM3-sg #113
<400> 414
gttgtttctg acattagcca 20
<210> 415
<211> 20
<212> DNA
<213> Cas-TIM3-sg #114
<400> 415
accaccaggg gacatggccc 20
<210> 416
<211> 20
<212> DNA
<213> Cas-TIM3-sg #115
<400> 416
tccatagcaa atatccacat 20
<210> 417
<211> 20
<212> DNA
<213> Cas-TIM3-sg #116
<400> 417
aagagaagat acagaattta 20
<210> 418
<211> 20
<212> DNA
<213> Cas-TIM3-sg #117
<400> 418
tttccacagc ctcatctctt 20
<210> 419
<211> 20
<212> DNA
<213> Cas-TIM3-sg #118
<400> 419
tggccaaaga gatgaggctg 20
<210> 420
<211> 20
<212> DNA
<213> Cas-TIM3-sg #119
<400> 420
tatgagaata ccctagtaag 20
<210> 421
<211> 20
<212> DNA
<213> Cas-TIM3-sg #120
<400> 421
gccaatgtgg atatttgcta 20
<210> 422
<211> 20
<212> DNA
<213> Cas-TIM3-sg #121
<400> 422
aaagggaaga tgtgaaaaca 20
<210> 423
<211> 20
<212> DNA
<213> Cas-TIM3-sg #122
<400> 423
ttgggccaca attctctcct 20
<210> 424
<211> 20
<212> DNA
<213> Cas-TIM3-sg #123
<400> 424
ctatgcaggg tcctcagaag 20
<210> 425
<211> 20
<212> DNA
<213> Cas-TIM3-sg #124
<400> 425
aatgtgactc tagcagacag 20
<210> 426
<211> 20
<212> DNA
<213> Cas-TIM3-sg #125
<400> 426
gttgtttctg acattagcca 20
<210> 427
<211> 20
<212> DNA
<213> Cas-TIM3-sg #126
<400> 427
accaccaggg gacatggccc 20
<210> 428
<211> 20
<212> DNA
<213> Cas-TIM3-sg #127
<400> 428
tccatagcaa atatccacat 20
<210> 429
<211> 20
<212> DNA
<213> Cas-TIM3-sg #128
<400> 429
aagagaagat acagaattta 20
<210> 430
<211> 20
<212> DNA
<213> Cas-TIM3-sg #129
<400> 430
tttccacagc ctcatctctt 20
<210> 431
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #1
<400> 431
gccccagcag acgggcacga 20
<210> 432
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #2
<400> 432
catcagtcct gagcaccacg 20
<210> 433
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #3
<400> 433
agccagtatc tggatgtcca 20
<210> 434
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #4
<400> 434
gcggaaatcc ccatttagcc 20
<210> 435
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #5
<400> 435
ggatccggca gcagtagatc 20
<210> 436
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #6
<400> 436
catcattcat tatgcctggg 20
<210> 437
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #7
<400> 437
gatgaccaac ttcaggttaa 20
<210> 438
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #8
<400> 438
atatcaggga ggctccccag 20
<210> 439
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #9
<400> 439
gtgttagatt tatatcaggg 20
<210> 440
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #10
<400> 440
gaaaattaaa gcgccgaaga 20
<210> 441
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #11
<400> 441
gctatgagaa taccatttga 20
<210> 442
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #12
<400> 442
gccaatcctg agggagggag 20
<210> 443
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #13
<400> 443
cttctgagcg aattccctct 20
<210> 444
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #14
<400> 444
tcacatcttc cctttgactg 20
<210> 445
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #15
<400> 445
cacatcttcc ctttgactgt 20
<210> 446
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #16
<400> 446
gactgtgtcc tgctgctgct 20
<210> 447
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #17
<400> 447
gaatgtggca acgtggtgct 20
<210> 448
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #18
<400> 448
ccgcaaagga gatgtgtccc 20
<210> 449
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #19
<400> 449
aacctgaagt tggtcatcaa 20
<210> 450
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #20
<400> 450
ccaaggatgc ttaccaccag 20
<210> 451
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #21
<400> 451
aattttcaaa tggtattctc 20
<210> 452
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #22
<400> 452
tcaaatggta ttctcatagc 20
<210> 453
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #23
<400> 453
aagcctcatc tctttggcca 20
<210> 454
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #24
<400> 454
gggttgtcgc tttgcaatgc 20
<210> 455
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #25
<400> 455
tcttctgcaa gctccatgtt 20
<210> 456
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #26
<400> 456
ctgacattag ccaaggtcac 20
<210> 457
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #27
<400> 457
ttatagcaga gacacagaca 20
<210> 458
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #28
<400> 458
tatagcagag acacagacac 20
<210> 459
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #29
<400> 459
atagcagaga cacagacact 20
<210> 460
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #30
<400> 460
gtgtttccat agcaaatatc 20
<210> 461
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #31
<400> 461
ccatagcaaa tatccacatt 20
<210> 462
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #32
<400> 462
cccccttact agggtattct 20
<210> 463
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #33
<400> 463
tgtttccccc ttactagggt 20
<210> 464
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #34
<400> 464
gtttccccct tactagggta 20
<210> 465
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #35
<400> 465
atttccacag cctcatctct 20
<210> 466
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #36
<400> 466
ccacagcctc atctctttgg 20
<210> 467
<211> 20
<212> DNA
<213> Cpf-TIM3-sg #37
<400> 467
gcaatgccat agatccaacc 20
<210> 468
<211> 20
<212> DNA
<213> Cas-PD1-sg #1
<400> 468
tgtagcaccg cccagacgac 20
<210> 469
<211> 20
<212> DNA
<213> Cas-PD1-sg #2
<400> 469
cgtctgggcg gtgctacaac 20
<210> 470
<211> 20
<212> DNA
<213> Cas-PD1-sg #3
<400> 470
gtctgggcgg tgctacaact 20
<210> 471
<211> 20
<212> DNA
<213> Cas-PD1-sg #4
<400> 471
aggcgccctg gccagtcgtc 20
<210> 472
<211> 20
<212> DNA
<213> Cas-PD1-sg #5
<400> 472
caccgcccag acgactggcc 20
<210> 473
<211> 20
<212> DNA
<213> Cas-PD1-sg #6
<400> 473
atgtggaagt cacgcccgtt 20
<210> 474
<211> 20
<212> DNA
<213> Cas-PD1-sg #7
<400> 474
catgtggaag tcacgcccgt 20
<210> 475
<211> 20
<212> DNA
<213> Cas-PD1-sg #8
<400> 475
cacgaagctc tccgatgtgt 20
<210> 476
<211> 20
<212> DNA
<213> Cas-PD1-sg #9
<400> 476
cggagagctt cgtgctaaac 20
<210> 477
<211> 20
<212> DNA
<213> Cas-PD1-sg #10
<400> 477
cctgctcgtg gtgaccgaag 20
<210> 478
<211> 9288
<212> DNA
<213> PMH001-CAS9
<400> 478
gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag 60
ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120
aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180
atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240
cgaaacaccg ggtcttcgag aagacctgtt ttagagctag aaatagcaag ttaaaataag 300
gctagtccgt tatcaacttg aaaaagtggc accgagtcgg tgcttttttg ttttagagct 360
agaaatagca agttaaaata aggctagtcc gtttttagcg cgtgcgccaa ttctgcagac 420
aaatggctct agaggtaccc gttacataac ttacggtaaa tggcccgcct ggctgaccgc 480
ccaacgaccc ccgcccattg acgtcaatag taacgccaat agggactttc cattgacgtc 540
aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc 600
caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tgtgcccagt 660
acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta 720
ccatggtcga ggtgagcccc acgttctgct tcactctccc catctccccc ccctccccac 780
ccccaatttt gtatttattt attttttaat tattttgtgc agcgatgggg gcgggggggg 840
ggggggggcg cgcgccaggc ggggcggggc ggggcgaggg gcggggcggg gcgaggcgga 900
gaggtgcggc ggcagccaat cagagcggcg cgctccgaaa gtttcctttt atggcgaggc 960
ggcggcggcg gcggccctat aaaaagcgaa gcgcgcggcg ggcgggagtc gctgcgcgct 1020
gccttcgccc cgtgccccgc tccgccgccg cctcgcgccg cccgccccgg ctctgactga 1080
ccgcgttact cccacaggtg agcgggcggg acggcccttc tcctccgggc tgtaattagc 1140
tgagcaagag gtaagggttt aagggatggt tggttggtgg ggtattaatg tttaattacc 1200
tggagcacct gcctgaaatc actttttttc aggttggacc ggtgccacca tggactataa 1260
ggaccacgac ggagactaca aggatcatga tattgattac aaagacgatg acgataagat 1320
ggccccaaag aagaagcgga aggtcggtat ccacggagtc ccagcagccg acaagaagta 1380
cagcatcggc ctggacatcg gcaccaactc tgtgggctgg gccgtgatca ccgacgagta 1440
caaggtgccc agcaagaaat tcaaggtgct gggcaacacc gaccggcaca gcatcaagaa 1500
gaacctgatc ggagccctgc tgttcgacag cggcgaaaca gccgaggcca cccggctgaa 1560
gagaaccgcc agaagaagat acaccagacg gaagaaccgg atctgctatc tgcaagagat 1620
cttcagcaac gagatggcca aggtggacga cagcttcttc cacagactgg aagagtcctt 1680
cctggtggaa gaggataaga agcacgagcg gcaccccatc ttcggcaaca tcgtggacga 1740
ggtggcctac cacgagaagt accccaccat ctaccacctg agaaagaaac tggtggacag 1800
caccgacaag gccgacctgc ggctgatcta tctggccctg gcccacatga tcaagttccg 1860
gggccacttc ctgatcgagg gcgacctgaa ccccgacaac agcgacgtgg acaagctgtt 1920
catccagctg gtgcagacct acaaccagct gttcgaggaa aaccccatca acgccagcgg 1980
cgtggacgcc aaggccatcc tgtctgccag actgagcaag agcagacggc tggaaaatct 2040
gatcgcccag ctgcccggcg agaagaagaa tggcctgttc ggaaacctga ttgccctgag 2100
cctgggcctg acccccaact tcaagagcaa cttcgacctg gccgaggatg ccaaactgca 2160
gctgagcaag gacacctacg acgacgacct ggacaacctg ctggcccaga tcggcgacca 2220
gtacgccgac ctgtttctgg ccgccaagaa cctgtccgac gccatcctgc tgagcgacat 2280
cctgagagtg aacaccgaga tcaccaaggc ccccctgagc gcctctatga tcaagagata 2340
cgacgagcac caccaggacc tgaccctgct gaaagctctc gtgcggcagc agctgcctga 2400
gaagtacaaa gagattttct tcgaccagag caagaacggc tacgccggct acattgacgg 2460
cggagccagc caggaagagt tctacaagtt catcaagccc atcctggaaa agatggacgg 2520
caccgaggaa ctgctcgtga agctgaacag agaggacctg ctgcggaagc agcggacctt 2580
cgacaacggc agcatccccc accagatcca cctgggagag ctgcacgcca ttctgcggcg 2640
gcaggaagat ttttacccat tcctgaagga caaccgggaa aagatcgaga agatcctgac 2700
cttccgcatc ccctactacg tgggccctct ggccagggga aacagcagat tcgcctggat 2760
gaccagaaag agcgaggaaa ccatcacccc ctggaacttc gaggaagtgg tggacaaggg 2820
cgcttccgcc cagagcttca tcgagcggat gaccaacttc gataagaacc tgcccaacga 2880
gaaggtgctg cccaagcaca gcctgctgta cgagtacttc accgtgtata acgagctgac 2940
caaagtgaaa tacgtgaccg agggaatgag aaagcccgcc ttcctgagcg gcgagcagaa 3000
aaaggccatc gtggacctgc tgttcaagac caaccggaaa gtgaccgtga agcagctgaa 3060
agaggactac ttcaagaaaa tcgagtgctt cgactccgtg gaaatctccg gcgtggaaga 3120
tcggttcaac gcctccctgg gcacatacca cgatctgctg aaaattatca aggacaagga 3180
cttcctggac aatgaggaaa acgaggacat tctggaagat atcgtgctga ccctgacact 3240
gtttgaggac agagagatga tcgaggaacg gctgaaaacc tatgcccacc tgttcgacga 3300
caaagtgatg aagcagctga agcggcggag atacaccggc tggggcaggc tgagccggaa 3360
gctgatcaac ggcatccggg acaagcagtc cggcaagaca atcctggatt tcctgaagtc 3420
cgacggcttc gccaacagaa acttcatgca gctgatccac gacgacagcc tgacctttaa 3480
agaggacatc cagaaagccc aggtgtccgg ccagggcgat agcctgcacg agcacattgc 3540
caatctggcc ggcagccccg ccattaagaa gggcatcctg cagacagtga aggtggtgga 3600
cgagctcgtg aaagtgatgg gccggcacaa gcccgagaac atcgtgatcg aaatggccag 3660
agagaaccag accacccaga agggacagaa gaacagccgc gagagaatga agcggatcga 3720
agagggcatc aaagagctgg gcagccagat cctgaaagaa caccccgtgg aaaacaccca 3780
gctgcagaac gagaagctgt acctgtacta cctgcagaat gggcgggata tgtacgtgga 3840
ccaggaactg gacatcaacc ggctgtccga ctacgatgtg gaccatatcg tgcctcagag 3900
ctttctgaag gacgactcca tcgacaacaa ggtgctgacc agaagcgaca agaaccgggg 3960
caagagcgac aacgtgccct ccgaagaggt cgtgaagaag atgaagaact actggcggca 4020
gctgctgaac gccaagctga ttacccagag aaagttcgac aatctgacca aggccgagag 4080
aggcggcctg agcgaactgg ataaggccgg cttcatcaag agacagctgg tggaaacccg 4140
gcagatcaca aagcacgtgg cacagatcct ggactcccgg atgaacacta agtacgacga 4200
gaatgacaag ctgatccggg aagtgaaagt gatcaccctg aagtccaagc tggtgtccga 4260
tttccggaag gatttccagt tttacaaagt gcgcgagatc aacaactacc accacgccca 4320
cgacgcctac ctgaacgccg tcgtgggaac cgccctgatc aaaaagtacc ctaagctgga 4380
aagcgagttc gtgtacggcg actacaaggt gtacgacgtg cggaagatga tcgccaagag 4440
cgagcaggaa atcggcaagg ctaccgccaa gtacttcttc tacagcaaca tcatgaactt 4500
tttcaagacc gagattaccc tggccaacgg cgagatccgg aagcggcctc tgatcgagac 4560
aaacggcgaa accggggaga tcgtgtggga taagggccgg gattttgcca ccgtgcggaa 4620
agtgctgagc atgccccaag tgaatatcgt gaaaaagacc gaggtgcaga caggcggctt 4680
cagcaaagag tctatcctgc ccaagaggaa cagcgataag ctgatcgcca gaaagaagga 4740
ctgggaccct aagaagtacg gcggcttcga cagccccacc gtggcctatt ctgtgctggt 4800
ggtggccaaa gtggaaaagg gcaagtccaa gaaactgaag agtgtgaaag agctgctggg 4860
gatcaccatc atggaaagaa gcagcttcga gaagaatccc atcgactttc tggaagccaa 4920
gggctacaaa gaagtgaaaa aggacctgat catcaagctg cctaagtact ccctgttcga 4980
gctggaaaac ggccggaaga gaatgctggc ctctgccggc gaactgcaga agggaaacga 5040
actggccctg ccctccaaat atgtgaactt cctgtacctg gccagccact atgagaagct 5100
gaagggctcc cccgaggata atgagcagaa acagctgttt gtggaacagc acaagcacta 5160
cctggacgag atcatcgagc agatcagcga gttctccaag agagtgatcc tggccgacgc 5220
taatctggac aaagtgctgt ccgcctacaa caagcaccgg gataagccca tcagagagca 5280
ggccgagaat atcatccacc tgtttaccct gaccaatctg ggagcccctg ccgccttcaa 5340
gtactttgac accaccatcg accggaagag gtacaccagc accaaagagg tgctggacgc 5400
caccctgatc caccagagca tcaccggcct gtacgagaca cggatcgacc tgtctcagct 5460
gggaggcgac aaaaggccgg cggccacgaa aaaggccggc caggcaaaaa agaaaaagga 5520
attcggcagt ggagagggca gaggaagtct gctaacatgc ggtgacgtcg aggagaatcc 5580
tggcccagtg agcaagggcg aggagctgtt caccggggtg gtgcccatcc tggtcgagct 5640
ggacggcgac gtaaacggcc acaagttcag cgtgtccggc gagggcgagg gcgatgccac 5700
ctacggcaag ctgaccctga agttcatctg caccaccggc aagctgcccg tgccctggcc 5760
caccctcgtg accaccctga cctacggcgt gcagtgcttc agccgctacc ccgaccacat 5820
gaagcagcac gacttcttca agtccgccat gcccgaaggc tacgtccagg agcgcaccat 5880
cttcttcaag gacgacggca actacaagac ccgcgccgag gtgaagttcg agggcgacac 5940
cctggtgaac cgcatcgagc tgaagggcat cgacttcaag gaggacggca acatcctggg 6000
gcacaagctg gagtacaact acaacagcca caacgtctat atcatggccg acaagcagaa 6060
gaacggcatc aaggtgaact tcaagatccg ccacaacatc gaggacggca gcgtgcagct 6120
cgccgaccac taccagcaga acacccccat cggcgacggc cccgtgctgc tgcccgacaa 6180
ccactacctg agcacccagt ccgccctgag caaagacccc aacgagaagc gcgatcacat 6240
ggtcctgctg gagttcgtga ccgccgccgg gatcactctc ggcatggacg agctgtacaa 6300
ggaattctaa ctagagctcg ctgatcagcc tcgactgtgc cttctagttg ccagccatct 6360
gttgtttgcc cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt 6420
tcctaataaa atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg 6480
ggtggggtgg ggcaggacag caagggggag gattgggaag agaatagcag gcatgctggg 6540
gagcggccgc aggaacccct agtgatggag ttggccactc cctctctgcg cgctcgctcg 6600
ctcactgagg ccgggcgacc aaaggtcgcc cgacgcccgg gctttgcccg ggcggcctca 6660
gtgagcgagc gagcgcgcag ctgcctgcag gggcgcctga tgcggtattt tctccttacg 6720
catctgtgcg gtatttcaca ccgcatacgt caaagcaacc atagtacgcg ccctgtagcg 6780
gcgcattaag cgcggcgggt gtggtggtta cgcgcagcgt gaccgctaca cttgccagcg 6840
ccttagcgcc cgctcctttc gctttcttcc cttcctttct cgccacgttc gccggctttc 6900
cccgtcaagc tctaaatcgg gggctccctt tagggttccg atttagtgct ttacggcacc 6960
tcgaccccaa aaaacttgat ttgggtgatg gttcacgtag tgggccatcg ccctgataga 7020
cggtttttcg ccctttgacg ttggagtcca cgttctttaa tagtggactc ttgttccaaa 7080
ctggaacaac actcaactct atctcgggct attcttttga tttataaggg attttgccga 7140
tttcggtcta ttggttaaaa aatgagctga tttaacaaaa atttaacgcg aattttaaca 7200
aaatattaac gtttacaatt ttatggtgca ctctcagtac aatctgctct gatgccgcat 7260
agttaagcca gccccgacac ccgccaacac ccgctgacgc gccctgacgg gcttgtctgc 7320
tcccggcatc cgcttacaga caagctgtga ccgtctccgg gagctgcatg tgtcagaggt 7380
tttcaccgtc atcaccgaaa cgcgcgagac gaaagggcct cgtgatacgc ctatttttat 7440
aggttaatgt catgataata atggtttctt agacgtcagg tggcactttt cggggaaatg 7500
tgcgcggaac ccctatttgt ttatttttct aaatacattc aaatatgtat ccgctcatga 7560
gacaataacc ctgataaatg cttcaataat attgaaaaag gaagagtatg agtattcaac 7620
atttccgtgt cgcccttatt cccttttttg cggcattttg ccttcctgtt tttgctcacc 7680
cagaaacgct ggtgaaagta aaagatgctg aagatcagtt gggtgcacga gtgggttaca 7740
tcgaactgga tctcaacagc ggtaagatcc ttgagagttt tcgccccgaa gaacgttttc 7800
caatgatgag cacttttaaa gttctgctat gtggcgcggt attatcccgt attgacgccg 7860
ggcaagagca actcggtcgc cgcatacact attctcagaa tgacttggtt gagtactcac 7920
cagtcacaga aaagcatctt acggatggca tgacagtaag agaattatgc agtgctgcca 7980
taaccatgag tgataacact gcggccaact tacttctgac aacgatcgga ggaccgaagg 8040
agctaaccgc ttttttgcac aacatggggg atcatgtaac tcgccttgat cgttgggaac 8100
cggagctgaa tgaagccata ccaaacgacg agcgtgacac cacgatgcct gtagcaatgg 8160
caacaacgtt gcgcaaacta ttaactggcg aactacttac tctagcttcc cggcaacaat 8220
taatagactg gatggaggcg gataaagttg caggaccact tctgcgctcg gcccttccgg 8280
ctggctggtt tattgctgat aaatctggag ccggtgagcg tggaagccgc ggtatcattg 8340
cagcactggg gccagatggt aagccctccc gtatcgtagt tatctacacg acggggagtc 8400
aggcaactat ggatgaacga aatagacaga tcgctgagat aggtgcctca ctgattaagc 8460
attggtaact gtcagaccaa gtttactcat atatacttta gattgattta aaacttcatt 8520
tttaatttaa aaggatctag gtgaagatcc tttttgataa tctcatgacc aaaatccctt 8580
aacgtgagtt ttcgttccac tgagcgtcag accccgtaga aaagatcaaa ggatcttctt 8640
gagatccttt ttttctgcgc gtaatctgct gcttgcaaac aaaaaaacca ccgctaccag 8700
cggtggtttg tttgccggat caagagctac caactctttt tccgaaggta actggcttca 8760
gcagagcgca gataccaaat actgttcttc tagtgtagcc gtagttaggc caccacttca 8820
agaactctgt agcaccgcct acatacctcg ctctgctaat cctgttacca gtggctgctg 8880
ccagtggcga taagtcgtgt cttaccgggt tggactcaag acgatagtta ccggataagg 8940
cgcagcggtc gggctgaacg gggggttcgt gcacacagcc cagcttggag cgaacgacct 9000
acaccgaact gagataccta cagcgtgagc tatgagaaag cgccacgctt cccgaaggga 9060
gaaaggcgga caggtatccg gtaagcggca gggtcggaac aggagagcgc acgagggagc 9120
ttccaggggg aaacgcctgg tatctttata gtcctgtcgg gtttcgccac ctctgacttg 9180
agcgtcgatt tttgtgatgc tcgtcagggg ggcggagcct atggaaaaac gccagcaacg 9240
cggccttttt acggttcctg gccttttgct ggccttttgc tcacatgt 9288
<210> 479
<211> 9409
<212> DNA
<213> PMH002-CPF1
<400> 479
gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag 60
ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120
aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180
atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240
cgaaacaccg taatttctac tcttgtagat gggtcttcga gaagaccttt tttttgtttt 300
agagctagaa atagcaagtt aaaataaggc tagtccgttt ttagcgcgtg cgccaattct 360
gcagacaaat ggctctagag gtacccgtta cataacttac ggtaaatggc ccgcctggct 420
gaccgcccaa cgacccccgc ccattgacgt caatagtaac gccaataggg actttccatt 480
gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt ggcagtacat caagtgtatc 540
atatgccaag tacgccccct attgacgtca atgacggtaa atggcccgcc tggcattgtg 600
cccagtacat gaccttatgg gactttccta cttggcagta catctacgta ttagtcatcg 660
ctattaccat ggtcgaggtg agccccacgt tctgcttcac tctccccatc tcccccccct 720
ccccaccccc aattttgtat ttatttattt tttaattatt ttgtgcagcg atgggggcgg 780
gggggggggg ggggcgcgcg ccaggcgggg cggggcgggg cgaggggcgg ggcggggcga 840
ggcggagagg tgcggcggca gccaatcaga gcggcgcgct ccgaaagttt ccttttatgg 900
cgaggcggcg gcggcggcgg ccctataaaa agcgaagcgc gcggcgggcg ggagtcgctg 960
cgcgctgcct tcgccccgtg ccccgctccg ccgccgcctc gcgccgcccg ccccggctct 1020
gactgaccgc gttactccca caggtgagcg ggcgggacgg cccttctcct ccgggctgta 1080
attagctgag caagaggtaa gggtttaagg gatggttggt tggtggggta ttaatgttta 1140
attacctgga gcacctgcct gaaatcactt tttttcaggt tggaccggtg ccaccatgga 1200
ctataaggac cacgacggag actacaagga tcatgatatt gattacaaag acgatgacga 1260
taagatggcc ccaaagaaga agcggaaggt cggtatccac ggagtcccag cagccgacaa 1320
gaagtacagc atcggcctgg acatcggcac caactctgtg ggctgggccg tgatcaccga 1380
cgagtacaag gtgcccagca agaaattcaa ggtgctgggc aacaccgacc ggcacagcat 1440
caagaagaac ctgatcggag ccctgctgtt cgacagcggc gaaacagccg aggccacccg 1500
gctgaagaga accgccagaa gaagatacac cagacggaag aaccggatct gctatctgca 1560
agagatcttc agcaacgaga tgacacagtt cgagggcttt accaacctgt atcaggtgag 1620
caagacactg cggtttgagc tgatcccaca gggcaagacc ctgaagcaca tccaggagca 1680
gggcttcatc gaggaggaca aggcccgcaa tgatcactac aaggagctga agcccatcat 1740
cgatcggatc tacaagacct atgccgacca gtgcctgcag ctggtgcagc tggattggga 1800
gaacctgagc gccgccatcg actcctatag aaaggagaaa accgaggaga caaggaacgc 1860
cctgatcgag gagcaggcca catatcgcaa tgccatccac gactacttca tcggccggac 1920
agacaacctg accgatgcca tcaataagag acacgccgag atctacaagg gcctgttcaa 1980
ggccgagctg tttaatggca aggtgctgaa gcagctgggc accgtgacca caaccgagca 2040
cgagaacgcc ctgctgcgga gcttcgacaa gtttacaacc tacttctccg gcttttatga 2100
gaacaggaag aacgtgttca gcgccgagga tatcagcaca gccatcccac accgcatcgt 2160
gcaggacaac ttccccaagt ttaaggagaa ttgtcacatc ttcacacgcc tgatcaccgc 2220
cgtgcccagc ctgcgggagc actttgagaa cgtgaagaag gccatcggca tcttcgtgag 2280
cacctccatc gaggaggtgt tttccttccc tttttataac cagctgctga cacagaccca 2340
gatcgacctg tataaccagc tgctgggagg aatctctcgg gaggcaggca ccgagaagat 2400
caagggcctg aacgaggtgc tgaatctggc catccagaag aatgatgaga cagcccacat 2460
catcgcctcc ctgccacaca gattcatccc cctgtttaag cagatcctgt ccgataggaa 2520
caccctgtct ttcatcctgg aggagtttaa gagcgacgag gaagtgatcc agtccttctg 2580
caagtacaag acactgctga gaaacgagaa cgtgctggag acagccgagg ccctgtttaa 2640
cgagctgaac agcatcgacc tgacacacat cttcatcagc cacaagaagc tggagacaat 2700
cagcagcgcc ctgtgcgacc actgggatac actgaggaat gccctgtatg agcggagaat 2760
ctccgagctg acaggcaaga tcaccaagtc tgccaaggag aaggtgcagc gcagcctgaa 2820
gcacgaggat atcaacctgc aggagatcat ctctgccgca ggcaaggagc tgagcgaggc 2880
cttcaagcag aaaaccagcg agatcctgtc ccacgcacac gccgccctgg atcagccact 2940
gcctacaacc ctgaagaagc aggaggagaa ggagatcctg aagtctcagc tggacagcct 3000
gctgggcctg taccacctgc tggactggtt tgccgtggat gagtccaacg aggtggaccc 3060
cgagttctct gcccggctga ccggcatcaa gctggagatg gagccttctc tgagcttcta 3120
caacaaggcc agaaattatg ccaccaagaa gccctactcc gtggagaagt tcaagctgaa 3180
ctttcagatg cctacactgg cctctggctg ggacgtgaat aaggagaaga acaatggcgc 3240
catcctgttt gtgaagaacg gcctgtacta tctgggcatc atgccaaagc agaagggcag 3300
gtataaggcc ctgagcttcg agcccacaga gaaaaccagc gagggctttg ataagatgta 3360
ctatgactac ttccctgatg ccgccaagat gatcccaaag tgcagcaccc agctgaaggc 3420
cgtgacagcc cactttcaga cccacacaac ccccatcctg ctgtccaaca atttcatcga 3480
gcctctggag atcacaaagg agatctacga cctgaacaat cctgagaagg agccaaagaa 3540
gtttcagaca gcctacgcca agaaaaccgg cgaccagaag ggctacagag aggccctgtg 3600
caagtggatc gacttcacaa gggattttct gtccaagtat accaagacaa cctctatcga 3660
tctgtctagc ctgcggccat cctctcagta taaggacctg ggcgagtact atgccgagct 3720
gaatcccctg ctgtaccaca tcagcttcca gagaatcgcc gagaaggaga tcatggatgc 3780
cgtggagaca ggcaagctgt acctgttcca gatctataac aaggactttg ccaagggcca 3840
ccacggcaag cctaatctgc acacactgta ttggaccggc ctgttttctc cagagaacct 3900
ggccaagaca agcatcaagc tgaatggcca ggccgagctg ttctaccgcc ctaagtccag 3960
gatgaagagg atggcacacc ggctgggaga gaagatgctg aacaagaagc tgaaggatca 4020
gaaaacccca atccccgaca ccctgtacca ggagctgtac gactatgtga atcacagact 4080
gtcccacgac ctgtctgatg aggccagggc cctgctgccc aacgtgatca ccaaggaggt 4140
gtctcacgag atcatcaagg ataggcgctt taccagcgac aagttctttt tccacgtgcc 4200
tatcacactg aactatcagg ccgccaattc cccatctaag ttcaaccaga gggtgaatgc 4260
ctacctgaag gagcaccccg agacacctat catcggcatc gatcggggcg agagaaacct 4320
gatctatatc acagtgatcg actccaccgg caagatcctg gagcagcgga gcctgaacac 4380
catccagcag tttgattacc agaagaagct ggacaacagg gagaaggaga gggtggcagc 4440
aaggcaggcc tggtctgtgg tgggcacaat caaggatctg aagcagggct atctgagcca 4500
ggtcatccac gagatcgtgg acctgatgat ccactaccag gccgtggtgg tgctggagaa 4560
cctgaatttc ggctttaaga gcaagaggac cggcatcgcc gagaaggccg tgtaccagca 4620
gttcgagaag atgctgatcg ataagctgaa ttgcctggtg ctgaaggact atccagcaga 4680
gaaagtggga ggcgtgctga acccatacca gctgacagac cagttcacct cctttgccaa 4740
gatgggcacc cagtctggct tcctgtttta cgtgcctgcc ccatatacat ctaagatcga 4800
tcccctgacc ggcttcgtgg accccttcgt gtggaaaacc atcaagaatc acgagagccg 4860
caagcacttc ctggagggct tcgactttct gcactacgac gtgaaaaccg gcgacttcat 4920
cctgcacttt aagatgaaca gaaatctgtc cttccagagg ggcctgcccg gctttatgcc 4980
tgcatgggat atcgtgttcg agaagaacga gacacagttt gacgccaagg gcaccccttt 5040
catcgccggc aagagaatcg tgccagtgat cgagaatcac agattcaccg gcagataccg 5100
ggacctgtat cctgccaacg agctgatcgc cctgctggag gagaagggca tcgtgttcag 5160
ggatggctcc aacatcctgc caaagctgct ggagaatgac gattctcacg ccatcgacac 5220
catggtggcc ctgatccgca gcgtgctgca gatgcggaac tccaatgccg ccacaggcga 5280
ggactatatc aacagccccg tgcgcgatct gaatggcgtg tgcttcgact cccggtttca 5340
gaacccagag tggcccatgg acgccgatgc caatggcgcc taccacatcg ccctgaaggg 5400
ccagctgctg ctgaatcacc tgaaggagag caaggatctg aagctgcaga acggcatctc 5460
caatcaggac tggctggcct acatccagga gctgcgcaac aaaaggccgg cggccacgaa 5520
aaaggccggc caggcaaaaa agaaaaaggg atcctaccca tacgatgttc cagattacgc 5580
ttatccctac gacgtgcctg attatgcata cccatatgat gtccccgact atgcctaagg 5640
aattcggcag tggagagggc agaggaagtc tgctaacatg cggtgacgtc gaggagaatc 5700
ctggcccagt gagcaagggc gaggagctgt tcaccggggt ggtgcccatc ctggtcgagc 5760
tggacggcga cgtaaacggc cacaagttca gcgtgtccgg cgagggcgag ggcgatgcca 5820
cctacggcaa gctgaccctg aagttcatct gcaccaccgg caagctgccc gtgccctggc 5880
ccaccctcgt gaccaccctg acctacggcg tgcagtgctt cagccgctac cccgaccaca 5940
tgaagcagca cgacttcttc aagtccgcca tgcccgaagg ctacgtccag gagcgcacca 6000
tcttcttcaa ggacgacggc aactacaaga cccgcgccga ggtgaagttc gagggcgaca 6060
ccctggtgaa ccgcatcgag ctgaagggca tcgacttcaa ggaggacggc aacatcctgg 6120
ggcacaagct ggagtacaac tacaacagcc acaacgtcta tatcatggcc gacaagcaga 6180
agaacggcat caaggtgaac ttcaagatcc gccacaacat cgaggacggc agcgtgcagc 6240
tcgccgacca ctaccagcag aacaccccca tcggcgacgg ccccgtgctg ctgcccgaca 6300
accactacct gagcacccag tccgccctga gcaaagaccc caacgagaag cgcgatcaca 6360
tggtcctgct ggagttcgtg accgccgccg ggatcactct cggcatggac gagctgtaca 6420
aggaattcta actagagctc gctgatcagc ctcgactgtg ccttctagtt gccagccatc 6480
tgttgtttgc ccctcccccg tgccttcctt gaccctggaa ggtgccactc ccactgtcct 6540
ttcctaataa aatgaggaaa ttgcatcgca ttgtctgagt aggtgtcatt ctattctggg 6600
gggtggggtg gggcaggaca gcaaggggga ggattgggaa gagaatagca ggcatgctgg 6660
ggagcggccg caggaacccc tagtgatgga gttggccact ccctctctgc gcgctcgctc 6720
gctcactgag gccgggcgac caaaggtcgc ccgacgcccg ggctttgccc gggcggcctc 6780
agtgagcgag cgagcgcgca gctgcctgca ggggcgcctg atgcggtatt ttctccttac 6840
gcatctgtgc ggtatttcac accgcatacg tcaaagcaac catagtacgc gccctgtagc 6900
ggcgcattaa gcgcggcggg tgtggtggtt acgcgcagcg tgaccgctac acttgccagc 6960
gccttagcgc ccgctccttt cgctttcttc ccttcctttc tcgccacgtt cgccggcttt 7020
ccccgtcaag ctctaaatcg ggggctccct ttagggttcc gatttagtgc tttacggcac 7080
ctcgacccca aaaaacttga tttgggtgat ggttcacgta gtgggccatc gccctgatag 7140
acggtttttc gccctttgac gttggagtcc acgttcttta atagtggact cttgttccaa 7200
actggaacaa cactcaactc tatctcgggc tattcttttg atttataagg gattttgccg 7260
atttcggtct attggttaaa aaatgagctg atttaacaaa aatttaacgc gaattttaac 7320
aaaatattaa cgtttacaat tttatggtgc actctcagta caatctgctc tgatgccgca 7380
tagttaagcc agccccgaca cccgccaaca cccgctgacg cgccctgacg ggcttgtctg 7440
ctcccggcat ccgcttacag acaagctgtg accgtctccg ggagctgcat gtgtcagagg 7500
ttttcaccgt catcaccgaa acgcgcgaga cgaaagggcc tcgtgatacg cctattttta 7560
taggttaatg tcatgataat aatggtttct tagacgtcag gtggcacttt tcggggaaat 7620
gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta tccgctcatg 7680
agacaataac cctgataaat gcttcaataa tattgaaaaa ggaagagtat gagtattcaa 7740
catttccgtg tcgcccttat tccctttttt gcggcatttt gccttcctgt ttttgctcac 7800
ccagaaacgc tggtgaaagt aaaagatgct gaagatcagt tgggtgcacg agtgggttac 7860
atcgaactgg atctcaacag cggtaagatc cttgagagtt ttcgccccga agaacgtttt 7920
ccaatgatga gcacttttaa agttctgcta tgtggcgcgg tattatcccg tattgacgcc 7980
gggcaagagc aactcggtcg ccgcatacac tattctcaga atgacttggt tgagtactca 8040
ccagtcacag aaaagcatct tacggatggc atgacagtaa gagaattatg cagtgctgcc 8100
ataaccatga gtgataacac tgcggccaac ttacttctga caacgatcgg aggaccgaag 8160
gagctaaccg cttttttgca caacatgggg gatcatgtaa ctcgccttga tcgttgggaa 8220
ccggagctga atgaagccat accaaacgac gagcgtgaca ccacgatgcc tgtagcaatg 8280
gcaacaacgt tgcgcaaact attaactggc gaactactta ctctagcttc ccggcaacaa 8340
ttaatagact ggatggaggc ggataaagtt gcaggaccac ttctgcgctc ggcccttccg 8400
gctggctggt ttattgctga taaatctgga gccggtgagc gtggaagccg cggtatcatt 8460
gcagcactgg ggccagatgg taagccctcc cgtatcgtag ttatctacac gacggggagt 8520
caggcaacta tggatgaacg aaatagacag atcgctgaga taggtgcctc actgattaag 8580
cattggtaac tgtcagacca agtttactca tatatacttt agattgattt aaaacttcat 8640
ttttaattta aaaggatcta ggtgaagatc ctttttgata atctcatgac caaaatccct 8700
taacgtgagt tttcgttcca ctgagcgtca gaccccgtag aaaagatcaa aggatcttct 8760
tgagatcctt tttttctgcg cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca 8820
gcggtggttt gtttgccgga tcaagagcta ccaactcttt ttccgaaggt aactggcttc 8880
agcagagcgc agataccaaa tactgttctt ctagtgtagc cgtagttagg ccaccacttc 8940
aagaactctg tagcaccgcc tacatacctc gctctgctaa tcctgttacc agtggctgct 9000
gccagtggcg ataagtcgtg tcttaccggg ttggactcaa gacgatagtt accggataag 9060
gcgcagcggt cgggctgaac ggggggttcg tgcacacagc ccagcttgga gcgaacgacc 9120
tacaccgaac tgagatacct acagcgtgag ctatgagaaa gcgccacgct tcccgaaggg 9180
agaaaggcgg acaggtatcc ggtaagcggc agggtcggaa caggagagcg cacgagggag 9240
cttccagggg gaaacgcctg gtatctttat agtcctgtcg ggtttcgcca cctctgactt 9300
gagcgtcgat ttttgtgatg ctcgtcaggg gggcggagcc tatggaaaaa cgccagcaac 9360
gcggcctttt tacggttcct ggccttttgc tggccttttg ctcacatgt 9409
<210> 480
<211> 20
<212> DNA
<213> hLAG-3test-1
<400> 480
gaagaaacag aaacccaagt 20
<210> 481
<211> 19
<212> DNA
<213> hLAG-3test-2
<400> 481
gagttctctt gaccaccaa 19
<210> 482
<211> 18
<212> DNA
<213> hLAG-3test-3
<400> 482
gggctttctc atcctcaa 18
<210> 483
<211> 18
<212> DNA
<213> hLAG-3test-4
<400> 483
gggtgacaca atctctcc 18
<210> 484
<211> 18
<212> DNA
<213> hTIM-3test-1
<400> 484
cagcgaatca tcctccaa 18
<210> 485
<211> 21
<212> DNA
<213> hTIM-3test-2
<400> 485
gagatgagaa caatcagtac c 21
<210> 486
<211> 19
<212> DNA
<213> hLAG-3test-5
<400> 486
ctgctctgtt ccctgggac 19
<210> 487
<211> 20
<212> DNA
<213> hLAG-3test-6
<400> 487
acttgggttt ctgtttcttc 20
<210> 488
<211> 20
<212> DNA
<213> hLAG-3test-7
<400> 488
caagggtggc tgatgccaag 20
<210> 489
<211> 20
<212> DNA
<213> hLAG-3test-8
<400> 489
tatacatgat ggagacgttg 20
<210> 490
<211> 20
<212> DNA
<213> hLAG-3test-9
<400> 490
ctgagcctcc tcagctcatc 20
<210> 491
<211> 20
<212> DNA
<213> hLAG-3test-10
<400> 491
agatgggcag gctctggaac 20
<210> 492
<211> 20
<212> DNA
<213> hLAG-3test-11
<400> 492
cacacctgta atcccagcac 20
<210> 493
<211> 20
<212> DNA
<213> hLAG-3test-12
<400> 493
gacagctctg tgaagtacac 20
<210> 494
<211> 20
<212> DNA
<213> hTIM-3test-3
<400> 494
caggaactct agcagttgag 20
<210> 495
<211> 20
<212> DNA
<213> hTIM-3test-4
<400> 495
catcattcat tatgcctggg 20
<210> 496
<211> 20
<212> DNA
<213> hTIM-3test-5
<400> 496
actcaccgct tgagtcttgg 20
<210> 497
<211> 19
<212> DNA
<213> hTIM-3test-6
<400> 497
ggtgttaaat atcactgag 19
Claims (9)
1.基于CRISPR特异性靶向人TIM-3基因的sgRNA,其特征在于:所述sgRNA依照下述原则设计:
(1)a.基于Cas9,在人TIM-3基因上选择5’-N(21)GG或者5’-N(21)AG;或,
b.基于Cpf1,在TIM-3基因上选择5’TTTN(20)序列;
(2)sgRNA在靶基因上的靶向位点或者剪切位点位于基因的外显子;
(3)sgRNA在靶基因上的靶向位点或者剪切位点位于不同的各种剪切形式的共有外显子上;
(4)在UCSC数据库中用Blat或NCBI数据库中用BLAST,确定sgRNA的靶序列是否唯一;
优选的,所述基于Cas9的sgRNA的序列如SEQ ID NO.302-430所示;更优选的,所述基于Cas9的sgRNA的序列如SEQ ID NO.503-707、310、312、313所示;
优选的,所述基于Cpf1的sgRNA的序列如SEQ ID NO.431-467所示;更优选的,所述基于Cpf1的sgRNA的序列如SEQ ID NO.431-436所示。
2.一种基因编辑载体,其特征在于,包含权利要求1所述sgRNA;优选的,权利要求1所述sgRNA连接于初始载体PMH001-Cas9或PMH002-Cpf1,所述PMH001-Cas9的核苷酸序列如SEQID NO.478所示,所述PMH002-Cpf1的核苷酸序列如SEQ ID NO.479所示。
3.一种基因重组病毒颗粒,其特征在于,所述病毒颗粒包含权利要求1所述sgRNA或权利要求2所述载体;所述病毒可选自逆转录病毒,慢病毒,腺病毒,腺相关病毒中的一种或几种。
4.一种基于CRISPR系统特异性敲除人TIM-3基因的方法,其特征在于,包含如下步骤:
1)基于Cas9或Cpf1设计特异性靶向人TIM-3基因的sgRNA;
2)构建合成步骤1)所述sgRNA的寡聚核苷酸双链;
3)将步骤2)所述sgRNA的寡聚核苷酸双链连接入带有Cas9或Cpf1内切酶的表达载体,鉴定阳性克隆,获得基因编辑载体;
4)将步骤3)获得的基因编辑载体转入人类细胞中,即可完成对TIM-3基因的敲除。
5.根据权利要求4所述方法获得的人类细胞,其特征在于,所述人类细胞不包含胚胎干细胞,优选的,所述细胞为人类T细胞。
6.一种试剂盒,其特征在于,包含权利要求1所述sgRNA,和/或权利要求2所述基因编辑载体,和/或权利要求3所述病毒颗粒,和/或权利要求5所述细胞。
7.一种免疫检查点经过基因编辑的T细胞,其特征在于,LAG-3、TIM-3或PD-1中的一个或多个位点被敲除,所述敲除基于CRISPR系统实现;优选使用权利要求1所述sgRNA进行基因敲除。
8.一种抑制人肿瘤细胞增殖的方法,其特征在于,使用权利要求5或7所述细胞与人肿瘤细胞共培养;所述人肿瘤选自肺癌、胃癌、肝癌和/或乳腺癌;所述肿瘤细胞可选自MHCC97H,LM3,SMCC7721,HepG2,Hep3B,A549,SPC-A1,NCI-H1650,NCI-H1975,NCI-H460,SK-MES-1,MKN-45,MGC-803,NCI-N87,SNU-5,KATO III,HGC-27,BGC-823,SGC-7901,AGS,Bcap-37,MCF-7或SKBR3。
9.权利要求1所述sgRNA、权利要求2所述载体、权利要求3所述病毒颗粒、和/或权利要求5或权利要求7所述细胞在用于制备治疗人肿瘤的药物和/或制剂中的用途,所述肿瘤优选肺癌、胃癌、肝癌或乳腺癌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611231819.4A CN107760680B (zh) | 2016-12-28 | 2016-12-28 | 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611231819.4A CN107760680B (zh) | 2016-12-28 | 2016-12-28 | 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107760680A true CN107760680A (zh) | 2018-03-06 |
CN107760680B CN107760680B (zh) | 2020-09-22 |
Family
ID=61263758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611231819.4A Expired - Fee Related CN107760680B (zh) | 2016-12-28 | 2016-12-28 | 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107760680B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108949693A (zh) * | 2018-07-30 | 2018-12-07 | 苏州茂行生物科技有限公司 | 一种对t细胞免疫检测点通路进行基因敲除的方法及应用 |
WO2019237390A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 一种敲除人hdmx基因的方法 |
CN109112129B (zh) * | 2018-08-29 | 2021-03-19 | 暨南大学 | 用于靶向敲除人OC-2基因的特异性sgRNA及应用 |
EP4039808A1 (en) * | 2021-02-08 | 2022-08-10 | Ospedale San Raffaele S.r.l. | Guide rnas and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
CN105378067A (zh) * | 2013-05-13 | 2016-03-02 | 塞勒克提斯公司 | 工程化用于免疫治疗的高活性t细胞的方法 |
WO2016183041A2 (en) * | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
WO2016183345A1 (en) * | 2015-05-13 | 2016-11-17 | Seattle Children' S Hospital (Dba Seattle Children 's Research Institute) | Enhancing endonuclease based gene editing in primary cells |
-
2016
- 2016-12-28 CN CN201611231819.4A patent/CN107760680B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105378067A (zh) * | 2013-05-13 | 2016-03-02 | 塞勒克提斯公司 | 工程化用于免疫治疗的高活性t细胞的方法 |
WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
WO2016183041A2 (en) * | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
WO2016183345A1 (en) * | 2015-05-13 | 2016-11-17 | Seattle Children' S Hospital (Dba Seattle Children 's Research Institute) | Enhancing endonuclease based gene editing in primary cells |
Non-Patent Citations (2)
Title |
---|
GWIAZDA KAMILA S等: "《High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins》", 《MOLECULAR THERAPY》 * |
WOO SENG-RYONG等: "《Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape》", 《CANCER RESEARCH》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019237390A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 一种敲除人hdmx基因的方法 |
CN108949693A (zh) * | 2018-07-30 | 2018-12-07 | 苏州茂行生物科技有限公司 | 一种对t细胞免疫检测点通路进行基因敲除的方法及应用 |
CN109112129B (zh) * | 2018-08-29 | 2021-03-19 | 暨南大学 | 用于靶向敲除人OC-2基因的特异性sgRNA及应用 |
EP4039808A1 (en) * | 2021-02-08 | 2022-08-10 | Ospedale San Raffaele S.r.l. | Guide rnas and uses thereof |
WO2022167694A1 (en) * | 2021-02-08 | 2022-08-11 | Ospedale San Raffaele S.R.L. | Guide rnas and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN107760680B (zh) | 2020-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107746845B (zh) | 特异性靶向LAG-3基因的sgRNA和特异性敲除LAG-3基因的方法 | |
AU2019204429B2 (en) | Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof | |
KR102451510B1 (ko) | Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법 | |
CN110856724B (zh) | 包含核酸及car修饰的免疫细胞的治疗剂及其应用 | |
CN107574179B (zh) | 一种为克鲁维酵母优化的CRISPR/Cas9高效基因编辑系统 | |
AU2017248259A1 (en) | Chimeric antigen receptor T cell compositions | |
KR102709329B1 (ko) | 개선된 면역 세포들 치료를 위한 타겟인 유전자 삽입 | |
CN111511903A (zh) | 用于改善的免疫细胞疗法的nk抑制剂基因的靶向基因整合 | |
CN107760680B (zh) | 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法 | |
CN111004330A (zh) | 一种制备非洲猪瘟病毒p30、p54酵母疫苗的方法 | |
AU2018235957B2 (en) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins | |
KR102317622B1 (ko) | Cas9 뉴클레아제를 암호화하는 핵산의 식이 제어된 발현 및 이의 용도 | |
US20240018542A1 (en) | Co-packaging to mitigate intermolecular recombination | |
CN113330023A (zh) | 体内具有crispr超级阻遏子的合成免疫调控 | |
CN106011133B (zh) | 一种小的dna分子量标准物、标准物质粒及其制备方法 | |
KR20240022575A (ko) | 아머링된 키메라 수용체 및 이의 사용 방법 | |
CN112312931A (zh) | X连锁高IgM综合征的治疗性基因组编辑 | |
CN108949690B (zh) | 一种制备可实时检测间充质干细胞骨分化的细胞模型的方法 | |
CN108949691B (zh) | 一种制备可实时检测间充质干细胞衰老的细胞模型的方法 | |
CN112272565A (zh) | 使用慢病毒基因构建体的递送的体内基因疗法 | |
CN110016481A (zh) | 一种pX335-xCas9n载体及其构建方法和应用 | |
US20240368632A1 (en) | Cells modified by a cas12i polypeptide | |
CN109082443A (zh) | 一种制备可实时检测间充质干细胞向成熟肝样细胞分化的细胞模型的方法 | |
RU2781083C2 (ru) | Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1 | |
RU2797304C2 (ru) | Целевая генная интеграция генов-ингибиторов nk для улучшенной иммунной клеточной терапии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200922 |